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ABSTRACT 
 
 Cancer is a leading cause of morbidity and mortality in the developed world. While much 
has been learned about these diseases in the last few decades, one of the main barriers to 
widespread advancement is the heterogeneity of cancer biology.  A growing body of evidence 
supports the idea that certain protein receptors are overexpressed on the surface of tumor cells as 
compared to normal tissues.  These extracellular biomarkers provide a unique opportunity to 
selectively target the tumor with both imaging and therapeutic modalities.  The research in this 
dissertation focuses on targeting proteins on the tumor cell surface with peptidomimetic ligands.   
Following a description of various extracellular receptors, chapter one discusses targeting 
ligands designed to specifically and selectively bind these receptors. It reviews recent literature on 
targeted alpha-particle therapy and ends with an explanation of the advantages of peptide ligands. 
Three distinct approaches to imaging and therapeutic modalities are then discussed in subsequent 
chapters. First, a peptide ligand was designed to target radionuclides to malignant melanoma cells 
in an effort to develop companion radiotherapeutics and diagnostic imaging agents. The second 
research project describes the synthesis of a novel antagonist peptide ligand with conjugated near 
infrared dye, and its utility for real-time intraoperative guidance during pancreatic adenocarcinoma 
resection.  Finally, the last chapter describes how the relatively new field of immunomodulatory 
effectors may be enhanced by their derivatization with peptide targeting ligands. 
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CHAPTER ONE: 
INTRODUCTION OF PEPTIDE TARGETING LIGANDS 
 
1.1 Cancer 
 
Advances in modern medicine are improving longevity; between 1990 and 2013, 
worldwide life expectancy has risen over 6 years, driven largely by advanced therapy for 
cardiovascular disease.1 With these longevity increases, chronic diseases have become the leading 
causes of death, with cancer now the second leading cause of death in the United States.1,2  The 
American Cancer Society projects 1.7 million new cancer diagnoses in 2016.3  Although 
prevention, early diagnosis, and better treatment options have slowed the rising cancer-related 
morbidity in recent decades, further research remains critical to the understanding of mechanisms 
by which tumors proliferate and evade destruction. This research is invaluable to both diagnostics 
and therapeutics, as the development of better imaging probes can detect aberrant cells earlier and 
the identification of innovative therapies can provide alternative treatments for patients with few 
clinical options.  
While still an amazingly complex process, the mechanisms by which tumors proliferate are 
increasingly becoming clearer.4 At the cellular level, the many diseases that are encompassed under 
the broad definition of cancer are quite heterogeneous.5 Much of this heterogeneity is understood 
to result from amplified expression of genes that have lower level expression in other normal 
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tissues.6 Fortunately, the overexpressed protein products of these genes can be leveraged to provide 
avenues by which cancers can be characterized and targeted for both diagnostics and therapeutics. 
Many of these overexpressed genes encode for transmembrane proteins expressed on the 
tumor cells.  Common types of these membrane bound proteins include G-protein coupled 
receptors (GPCRs) and receptor tyrosine kinases (RTKs). In fact the most abundant five cancers 
(breast, prostate, lung, colorectal, and cervical) are strongly associated with Erk/Akt activation 
resulting from RTK signaling at vascular endothelial growth factor  (VEGFRs), epidermal growth 
factor (EGFR), and human epidermal growth factor (HER2) cell surface receptors.7 The 
HER2/Neu receptor has been used to both characterize 15-30% of breast cancers, prognosticate, 
and treat the disease through innovative monoclonal antibody-based therapeutics.8 Folate receptor 
overexpression has been characterized in many malignancies while maintaining low expression in 
other normal tissues.9  Many GPCRs have been implicated in tumor progression through gene 
expression profiling.10 Our own collaborators at the Moffitt Cancer Center have described the 
overexpression of extracellular receptors in malignant melanomas11 and pancreatic 
adenocarcinomas12 by way of both tumor micro arrays (RNA expression profiling) and 
immunohistochemical (IHC) staining.   
 
1.2 Targeting the Tumor Cell Surface 
Philosophically, targeting the distinguishing cell surface features of cancer phenotypes is a 
type of personalized medicine. Because significant heterogeneity exists between different types of 
cancers as well as between different patients with the same type of cancer, maintaining a large tool 
box of targeted therapies may provide the most patient-directed therapy for a large number of 
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patients.  Overexpressed extracellular proteins are ideal targets not only because of comparatively 
lower expression in normal tissues, but because targeting ligands do not have to cross a cell 
membrane to interact with the protein allowing for selective targeting of imaging probes and 
therapeutics to cancerous cells.  
Classic examples of targeting cell surface receptors exist from the observation of folate 
receptor overexpression in many malignancies.  In 2011, a Dutch group published their 
development of a real-time intraoperative guided fluorescence imaging agent using folate 
conjugated FITC dye.13 The structure of their molecular probe is shown in Figure 1.1. This probe 
was used primary for staging and debulking epithelial ovarian cancers, but laid the framework for 
future near infrared fluorescent probes that could illuminate deeper tumors.  
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Figure 1.1. FITC targeted agent for folate receptor. Folate is colored blue, an ethylene diamine 
spacer is shaded green, and the fluorescein isothiocyanate (FITC) is shown in red. 
 
Targeted radiopharmaceuticals provide another avenue by which a targeting ligand can 
either provide diagnostic/imaging information or act as a therapeutic agent. Typically, targeting 
ligands are coupled with a chelating molecule that can complex a radionuclide.  The type of 
radioactive disintegration each radionuclide gives off determines how the targeting agent is used. 
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Emitted radiation may be in the form of high energy photons or positrons when used as imaging 
agents. Other categories of radionuclides emit β- and/or α- particles. Table 1.1 lists common α-
emitting radionuclides. Due to the high energies of these particles, they can be complexed as 
ligand-targeted payloads. These ‘smart bombs’ may then cause cellular damage to surrounding 
targeted tissues.14 As another example of folate receptor targeting, in 2014 a Swiss group 
complexed the α-emitting radionuclide Tb-149 to a folate analog.15 They demonstrated efficacy of 
their targeted therapy in a murine xenograft model by extending overall survival compared with 
control groups. The targeted delivery of α-emitting radionuclides is termed targeted alpha particle 
therapy (TAT).  
 
Table 1.1. Summary of common α-emitting radionuclides. 
Radionuclide Emitted Particle(s) Radioactive Half-Life (min) α-Particle Energy (meV) 
149Tb α (1) 252 4 
211At α (1) 432 6 
212Bi α (1), β (1) 60.6 6 
212Pb α (1), β (2) 636 6 
213Bi α (1), β (2) 46 7.8 
223Ra α (4), β (2) 16,416 6-7 
225Ac α (4), β (2) 14,400 6-8 
 
The most commonly utilized chelating molecules for targeted radionuclide therapies in 
conjunction with biological molecules are 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA), diethylene triamine pentaacetic acid (DTPA), and their related analogs (Figure 1.2). 
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Depending on the how the complexing agent is linked to the targeting ligand, these organic 
structures feature 3-4 carboxylates that are negatively charged at physiologic pH, and along with the 
lone pair electrons from each of the 3-4 nitrogens coordinate metal ions like α- and β- emitting 
radionuclides.  Often these chelating molecules are linked to the targeting molecule by forming a 
new amide bond between an amine on the targeting molecule and a carboxylate on the 
DOTA/DTPA.  This strategy is particularly advantageous in the case of peptide synthesis since the 
reaction, characterization and purification of the linker addition can be part of the overall 
synthesis of the targeting ligand.  
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Figure 1.2. Common metal chelators and binders used to attach radionuclides to targeting ligands.  
 
When DOTA/DTPA is linked to proteins like antibodies, amide bonds are often created 
between a primary amine of surface-exposed lysine residue and an activated carboxylate on the 
DOTA/DTPA (Scheme 1.1). Another widespread chemistry available to link protein lysines with 
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DOTA/DTPA is through an isothiocyanate which yields a stable thiourea (Scheme 1.1).16,17  While 
these newly formed amide bonds create the same covalent structure as the synthetic peptide 
conjugates, there are important distinctions. In the stochastic reaction of any accessible lysine, 
many different combinations are possible and there is little control over the regioselectivity of the 
conjugation. It is even possible that targeting ligands could block or hinder the antigen binding 
sites of the therapeutic antibody.  Therefore, site-specific modifications allow for control of the 
regioselectivity as well as avoidance of targeting ligand interference with antigen-antibody binding. 
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Scheme 1.1. Common conjugation chemistries used to functionalize biomolecules.  Row (a) and 
(b) show activated NHS and Sulfo-NHS esters reacting to form native amide bonds with lysine side 
chains from a biomolecule. Row (c) shows isothiocyanate reaction with the same lysine side chain 
on a biomolecule to from a stable thiourea bond. 
 
The importance of site-specific modifications to biologic targeting motifs has recently been 
studied. In a 2014 paper from UCLA,18diabodies (Dbs) were conjugated site-specifically through 
reduced cysteines and non-specifically through accessible lysine ε-amines to DOTA chelators. 
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While the tumor-to-blood ratio of the specifically labeled protein was moderately higher than the 
more heterogeneous product, the more striking result was the renal and hepatic distribution.  
Kidney uptake levels were almost doubled for the cysteine-labeled Db, and liver uptake levels were 
reduced for the non-specific amine-labeled Dbs.   
 
1.3 Targeting Molecules  
There is no one-size-fits-all answer to the question: what is the best targeting molecule? 
Rather, the abundance of target molecule classifications allow for a more customized approach to 
developing targeted agents.  Globally, the requirements of a targeting ligand include the ability to 
concentrate at, and bind to, extracellular targets and the availability of chemical functional groups 
amenable to the attachment of linkers and chelators. A balance of many other factors such as off-
target binding, biodistribution, and pharmacokinetics (particularly with respect to the decaying 
half-life of the chosen radionuclide) are also critical factors for selection of a proper targeting 
ligand. Peptides, antibodies, antibody fragments, and even some passive targeting strategies have 
been investigated to deliver radioisotope payloads.  
 
1.3.1 Antibodies 
Full length immunoglobulins (IgGs) are typically in the 150 kDa molecular weight range, 
and are understood to have high binding affinity and specificity to a broad range of extracellular 
receptors.  Developments in hybridoma cell line technology have opened the door to the 
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production of monoclonal antibodies (mAbs) which can be labeled with chelating molecules, to 
which radionuclides can be added. This approach to specifically deliver ionizing radiation payloads 
is termed radioimmunotherapy (RIT). While many of the examples listed in this section involve 
radioactive payloads directly conjugated to the protein, antibodies have also been employed to 
target macromolecular payloads such as nanoparticles and liposomes to cellular targets.19-21    
A research group based in the Memorial Sloan-Kettering Cancer Center (MSKCC) has 
reported several accounts of their work labeling trastuzumab with actinium 225. This mAb is the 
well-known and FDA approved HER2/ERRB2-targeting agent.   In the beginning, they showed 
using a spheroid in vitro model that their α-RIT scheme could penetrate spheroids, retard growth, 
and prevent regrowth of colonies in a dose dependent manner.22 While a promising start, this 
work underscored the importance of target expression and also suggested challenges of RIT due to 
the slow extravasation of targeting agents in normal tissues and toxicities of released/free decaying 
daughter products.23,24   
Also at MSKCC Scheinberg group’s work eventually led to the first clinical trial of an 
actinium-225 chelated targeted antibody.25 This α-RIT scheme utilized the previously explored 
humanized anti CD33 antibody, limtuzumab, to target acute myeloid leukemia cells. This work led 
to the birth of Actinium Pharmaceuticals and a portfolio of targeted 225Ac conjugated constructs in 
both preclinical and clinical pipelines.  
Other radionuclides in alternative labeling strategies have also been explored. In 2013 
Orozco and coworkers coupled a decaborate cage structure (B10, Figure 1.2) with astatine-211  to 
anti-CD45 antibodies in an attempt to target acute myeloid leukemia.26 More recently Green and 
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coworkers reported  anti-CD20 mAb conjugated with  211At in a similar B10 labeling scheme.27 
This study sought to eliminate minimal residual disease (MRD) in a mantle cell lymphoma animal 
model exploring both disseminated and xenograft models.  Interestingly, the disseminated disease 
model showed remarkable results with 70% disease eradication, while the subcutaneous 
lymphoma xenograft group had only modest benefit with no cured animals. Therefore while α-RIT 
is attractive for disseminated disease, benefits appear to be modest at best for bulkier tumors, 
highlighting the need for adequate tumor perfusion for the targeted alpha therapy to be fully 
effective.   
 
1.3.2 Antibody Fragments 
A limitation of full-size IgGs is their typical 1-3 week serum stability. While this durability 
may be advantageous for certain therapeutic applications, in RIT it can be serious liability.  Excess 
antibody can continue to circulate, lowering the tumor-to-nontumor (T/NT) ratio particularly with 
respect to the tumor-to-blood (T/B) ratio. Finally, high levels of continuously circulating alpha-
emitters results in hematological toxicities as well as extravasation in normal tissues.  
In attempts to shorten the long plasma half-life of full length antibodies, many groups have 
sought to reduce the size and stability of the mAb while retaining their advantageous binding 
characteristics. To this end antibodies have been modified through both enzymatic cleavage to 
smaller antibody fragments as well as de novo protein engineering.28,29  For comparison, the 
engineered antibody fragments of diabodies (Db) and minibodies (Mb) have typical circulating 
half-lives of 2-5 and 5-12 hours respectively, compared to 1-3 weeks for full-length IgG. Monovalent 
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and bivalent affibodies (7 and 15 kDa respectively) have been developed with targeting specificity 
to HER-2 and plasma half-lives of roughly 45 minutes.30  The science of antibodies is ever 
progressing and new classes are still being observed in nature; nanobodies (13-14 kDa) are heavy 
chain-only antibodies that have been isolated from Camelidae and have lately been conjugated with 
theranostic radionuclides.31 These new categories of targeting constructs are adding to the growing 
body of evidence that there may be a so-called ‘Goldilocks’ zone in terms of size of targeting 
constructs. 
 
1.3.3 Peptides 
Peptides are oligomers of amino acids that may exhibit secondary structure, include 
branched or linear frameworks, and may be composed of varying amounts of non-canonical 
monomers. The polypeptide chains of peptides can have anywhere from 2 to 70 amino acids but 
more typical examples of targeting peptides are made of less than 10-15 amino acids (1,000-1,500 
MW). Owing to this molecular weight and their capacity to be synthesized and modified with 
conventional organic synthesis techniques, peptides have long been utilized as targeting agents for 
radionuclide therapies and diagnostic applications.  
Since the 1980s, analogs of the endogenous peptide hormone somatostatin have been 
developed as therapeutics for neuroendocrine disorders.32 The FDA approved octreotide (OC, 
Figure 1.3) a cyclic octapeptide upon which much of the early peptide receptor radionuclide 
therapy (PRRT) was based. Chelating molecules were attached to octreotide and various 
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radionuclides for β- and α-emission therapies have been reported.  Figure 1.3 details the structure 
of OC and two of its commonly used PRRT ligand analogs, DOTATOC and DOTATATE.   
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Figure 1.3. The somatostatin mimetic octreotide and its DOTA- containing analogs. octreotide: R1 
= H, R2 = H, R3 = CH2OH; DOTATOC (endotreotide): R1 = DOTA, R2 = OH, R3 = CO2H; 
DOTATE (octreotate): R1 = DOTA, R2 = OH, R3 = CH2OH 
 
Nephrotoxicity is often one of the most pressing theoretical concerns with PRRT due to 
known reabsorption of the labeled peptide during glomerular filtration.33 This is especially 
problematic for beta therapy, more so than with alpha emitting therapies. The first published 
account of the alpha-emitter 213Bi in an OC analog (DOTATOC, Figure 1.3) was reported in 2006. 
The radio-peptide ligand was shown to retain its affinity for the somatostatin receptor and 
inhibited tumor growth in a somatostatin receptor-positive rat pancreatic tumor model 
(CA20948).34 Importantly the study followed major organ toxicities in rodents. Little to no 
nephro-, hepatic-, or hematological toxicities were observed in the various doses (13-22.2 Mbq).  
The organs with the most toxicity were the adrenals and the pancreas, both of which are known to 
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express low levels of somatostatin receptors. This favorable toxicity profile may be due, in part, to 
the limited range of the ejected α-particles and also the short radioactive half-life of 213Bi. 
Ultimately this study demonstrated that the high energy α-emitting radionuclides do not 
necessarily have the same toxicities of their β-emitting analogs and represent a more attractive 
therapy.  
In addition to its more favorable toxicity profile, alpha-emitting therapies have been shown 
to have improved efficacy over their beta-emitting counterparts. In a recent report, tumors that had 
become radioresitant to β-therapy (90Y and 190Lu – DOTATOC) responded to 213Bi-DOTATOC 
and cold octreotide therapy in a clinical model of 8 human patients.35  The treatment for each 
patient was individualized according to their particular disease state and all patients had 
substantially positive outcomes in terms of tumor regression and survival. Critically, the acute 
hematological toxicity normally associated with the analogous β-therapies were only moderate with 
alpha therapies. And where β-therapies are typically limited by their nephrotoxicity, this report 
suggested only mild reduction in acute renal function. No other major acute toxicities were 
reported. This first-in-human report of peptide-targeted alpha therapeutic may lay the ground work 
for future human TAT using peptide-targeted systems. 
 
1.4 Medicinal Chemistry of Targeting Ligands 
As previously touched upon, characteristics of various targeting ligands like lipophilicity, 
molecular weight, and ionization potential are all critical, and modifiable, variables that help 
modulate targeting ligand properties. For example, small, polar compounds are more likely to 
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undergo renal excretion and the addition of a PEG linker adds water solubility, bulk, and may 
help avoid kidney toxicities. Conversely, the removal of an ionizable group (eg. sulfonate or 
protonated amine at physiologic pH) during medicinal chemistry design may make the targeting 
ligand more hydrophobic and shift clearance predominantly to the liver. Therefore when working 
to reduce targeting ligand complexity or increase the ease of synthesis, these physical attributes of 
the compound must be considered. 
An example of the biology mantra, “structure begets function,” is exemplified in the 
vignette of constrained peptide ligands. Early work from Hruby and collaborators showed how 
subtle changes to an endogenous peptide hormone like oxytocin could induce conformational 
restrictions.36-38 By limiting available conformational space that the peptide can ‘sample,’ the more 
correct binding conformation may be found. From an entropic standpoint, enacting these 
constraints on the binding pharmacophore may yield a tighter binding ligand. Additionally, the 
change in ligand structure may have the effect of changing the function of the ligand. Whereas the 
comparatively floppy peptide ligand, oxytocin, was shown to bind to its receptor and ellicit 
downstream signaling, constraining the sequence with a penicillamine point mutation created an 
antagonist ligand that bound the receptor but inhibited signal transduction. Today synthetic 
oxytocin is approved clinically to hasten childbirth while constrained antagonist analogs are used 
to stop preterm labor.39 
Antibodies and engineered fragments can also benefit from medicinal chemistry 
optimization.  Many chelators and linkers covalently attached to antibodies and their fragments 
produce heterogeneous products. In the most typical fashion of linker attachment, surface 
accessible lysine side chains are utilized to form covalent bonds with radionuclide chelating 
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molecules (Scheme 1.1). Site specific antibody modifications can yield more homogeneous 
products. The Rader group at Scripps Florida has made such progress by engineering a 
selenocysteine residue into targeting antibodies, allowing for complete control of regiochemistry 
during functionalization due the increased nucleophilicity of selenium over sulfur.40 
Another route to increasing T/NT ratios is through pretargeting. These strategies operate 
under the premise that nonradiolabeled bifunctional targeting agents can be administered to the 
patient and allowed to sufficiently converge on their target. Once the unbound portion has 
cleared, a fraction of radiolabeled molecule with a binding affinity for the bifunctional targeting 
agent is administered. Typically, the radiolabeled agent is designed to clear quickly if unavailable 
for binding, thus lowering off target radiation.  Typical binding partners amenable to pretargeting 
schemes include avidin/streptravidin – biotin, DNA – DNA, and antibody- hapten interactions.41 
For a more in-depth analysis of pretargeting strategies please see the recent review article from 
Frampas and colleagues.42 
Other important research regarding linkers has uncovered different methods to reduce 
kidney toxicity due to the renal reabsorption of radiolabeled peptides and antibody fragments as 
they are filtered by the glomerulus.  By taking advantage of renal brush border enzymes, the 
radionuclide can be cleaved from targeting ligand and excreted.  By engineering an antibody 
fragment with C-terminal lysine, and subsequently modifying the ε-amine with DOTA:indium-
111, Li and coworkers demonstrated a 50-60% reduction in kidney uptake of the radionuclide.43 
More recently the Akizawa group probed the brush border enzymes to understand more about 
their specificity.  They were able to pinpoint a glycine-tyrosine linkage that specifically cleaved a 
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radio-iodinated benzoate derivative from an antibody Fab fragment.44 Presumably a similar 
approach could be used for the α-emitting halogen, 211At.  
Polyethylene glycol (PEG) linkers are made of repeating -CH2CH2O- monomers and are 
commonly employed by chemists to alter biodistribution and pharmacokinetics. PEGs can be 
prepared in two categories, polymeric and discrete oligomers. Bifunctionalized versions of these 
polymers can link targeting molecules with the chelating agent or just add bulk/solubility to 
smaller molecular weight entities.  Researchers wishing to reduce immunologic response to 
nanoparticles have been known to decorate their macromolecules with PEG19, as was the case with 
McLaughlin and coworkers with PEG12 linker used to link 4 nm, 225Ac containing, nanoparticles 
to mAb.45 
 
1.5 Vision for This Dissertation  
 
 Although there are advantages and disadvantages to both antibody- and peptide-based 
targeting molecules, the theme of this current research utilizes peptides as targeting ligands for 
many reasons. First, peptides may be synthesized using conventional organic chemistry techniques 
and through solid phase peptide synthesis.  Synthesis may use manual, automated, or a 
combination of both methods. There is a degree of control in these types of synthesis, which may 
be monitored, adapted, and optimized to create high purity, discrete ligands. Furthermore, the 
design of each peptide ligand may be engineered to include non-canonical amino acids and 
monomers. Structures may be branched and the attachment of various molecular payloads is 
straightforward. Overall, a chemist has remarkable control over the synthesis of peptide ligands.  
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Secondly, the physical and biological properties of our peptide ligands match the aims of our 
research projects.  All of our targets are cell surface receptors on vascularized tumor tissues not 
present in the central nervous system.  Peptide ligands are ideal for targeting these receptors since 
they do not passively cross cell membranes or the blood-brain barrier. Finally, the kinetics and 
distribution of our ligands are good matches for the various payloads they are capable of carrying, 
from α-emitting Ac225 to fluorescent dyes, and immune effectors.  
Each of the following three chapters in this dissertation contains a research project 
regarding a single extracellular receptor that is bonafide biomarker of a particular cancer type. 
Peptide ligands were designed and synthesized to have various targeting characteristics for each 
receptor. Furthermore, the peptide ligands were covalently attached to a different payload in each 
project, each with their own purpose. All of our targeting peptides have at least one imaging 
modality, and many have a therapeutic aim as well.  The overarching theme of this body of work is 
that peptides are effective targeting ligands for cancer imaging and therapeutic applications.  
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CHAPTER TWO: 
MELANOCORTIN 1 RECEPTOR TARGETING LIGANDS AND THE DEVELOPMENT 
OF A TARGETED RADIOPHARMACEUTICAL AND COMPANION DIAGNOSTIC 
IMAGING AGENT 
2.1 Introduction 
Although it accounts for just over one percent of all skin cancer diagnoses, melanoma is 
the most deadly type of skin cancer and the incidence continues to rise each year.1 With 
approximately 80,000 new diagnoses in 2016, the American Cancer Society estimates that over 
10,000 people will succumb to the disease this year.2  Cutaneous melanomas account for the 
majority of cases (91%), while uveal melanomas, for which there is little pharmacotherapy, make 
up roughly 3% of diagnoses.3,4  Melanoma is characterized as a malignancy of the melanocyte, 
present in the basal layer of the epidermis.  In normal tissues, these dendritic-like cells are 
responsible for skin pigmentation through melanin production. Given their proximity to blood 
vessels and the lymph system, melanoma often metastasizes quickly, necessitating systemic 
therapies as compared to localized excision common in other skin cancers.   
Clinical staging of melanoma is based on depth of tumor growth, lymph node involvement, 
and degree of metastases. Conventional therapies for cutaneous melanomas consist of wide 
surgical excision and external beam radiation which are particularly effective for early stage disease, 
and yield five and ten year survival rates of 92% and 89% respectively.2   However therapy for later 
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stage diseases is significantly less effective.  Five and ten year survival rates of malignant melanomas 
that have spread past their origin are 63% and 17% respectively.2 The poor prognosis, especially 
with late stage disease, coupled with the growing incidence of melanomas illustrates a definitive 
need for new treatments and diagnostic tools.   
Recent developments have shown differential gene and protein expression levels in subsets 
of melanomas. For instance, the variable expression of BRAF and NRAS mutations have been 
found in 58% of primary melanomas and 63% of metastases,5 and have led to new targeted 
therapies including small molecule inhibitors, dabrafenib6 and vemurafenib.7 While these and 
other non-conventional therapies8 show tremendous promise, they still leave a large portion of 
afflicted patients without targeted therapies.  The melanocortin-1 receptor (MC1R) has been 
found in 80% of cutaneous malignant melanomas and 95% of uveal melanomas according to 
mRNA expression,9 and the MC1R is expressed as protein in 97% of melanoma metastases (highly 
overexpressed in 50%).10 Furthermore the MC1R is expressed in 42% of metastases that aren’t 
candidates for current melanoma targeted therapy. 
The MC1R is one of five isotypes in a family of G-protein coupled receptors present on the 
surface of melanocytes.11  Isotypes of the receptor have variable expression in normal tissues like 
kidneys and lungs (MC5R), adrenal glands (MC2R), hypothalamus (MC3R), heart (MC4R), and 
brain, hair and skin (MC1R).  Because most peptides agents do not readily cross a normal blood-
brain barrier (BBB), it is easy to discover MC1R peptide ligands that do not concentrate in the 
brain.  Due to the high levels of MC1R cell-surface expression in skin, it serves as good biomarker 
of malignant, uveal, and metastatic melanomas, making it a potentially valuable target for imaging 
and targeted radiopharmaceuticals.   
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Melanotropins are a family of endogenous peptide hormones that are known to interact 
with melanocortin receptors.  Alpha-melanocyte stimulating (α-MSH) hormone is one such peptide 
that is a non-selective agonist, and is understood to help regulate appetite, metabolism, and sexual 
function. Based on the primary sequence of α-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
Lys-Pro-Val-COOH), a peptidomimetic was developed in the 1980s with high affinity and potency 
for MC1R (Ki = 1.8 nM).
12 This peptide included 2 point mutations at the 4- and 7- positions 
giving rise to the name 4Nle-7DPhe-α-MSH (NDP- α-MSH).  This melanotropin analog lacked 
selectivity for the MC1R, as it still bound to the MC4R and MC5R isotypes with Ki = 19 nM and 
9.9 nM, respectively.  
 Due to the value of MC1R as a biomarker, much SAR research has been done on the 
pharmacophore of α-MSH to increase its affinity and selectivity for the MC1R.13-16 The common 
pharmacophore in all analogs developed to date have been collectively referred to as the ‘message 
sequence,’ a section of four amino acids (His-DPhe-Arg-Trp) attributed to the binding affinity of 
the ligand.17 However it was not until the Morse group, in collaboration with BIO5 in Arizona, 
completed SAR work on both the C-and N- termini of the message sequence that acceptable 
selectivity was obtained.  Table 2.1 lists the most valuable analogs to emerge from this 
collaboration.18 The optimized ligand identified was one that capped the N-terminus with a 4-
phenylbutyric acid moiety and included a glycine spacer between the C-terminal lysine and the 
message sequence.  This compound (Figure 2.2) exhibits high selectivity for the MC1R over the 
MC4R and MC5R isotypes. 
Some groups have capitalized on the targeting ability of melanotropin analogs by arming 
the targeting ligands with payloads appropriate for imaging or cytotoxic therapies. Chen and 
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colleagues made use of the non-selective NDP-α-MSH to image tumors with an attachment of 
99mTc,19 while the Morse group and collaborators have examined the imaging capabilities of their 
lead melanotropin analog by attaching gadolinium-texaphyrin20 polymer micelles to the C-terminal 
lysine for magnetic resonance imaging.18,21  Despite the functionalization with relatively large (~90 
nm) micelles, the peptide ligand retained its selective targeting for the MC1R.  
Table 2.1. Select previously reported SAR work done on melanotropin message sequence.18  
No
. 
Structure 
Ki (nM) 
MC1
R 
MC4
R 
MC5
R 
1R/4
R 
1R/5
R 
1 4-phenylbutyryl-His-DPhe-Arg-Trp-NH2 0.17 160 27 950 160 
2 Ac-homophe-His-DPhe-Arg-Trp-NH2 1.8 988 58 560  
3 
4-phenylbutyryl-His-DPhe-Arg-Trp-Gly-Lys(hex-5-
ynoyl)-NH2 
0.24 254 46 1058 192 
4 NDP-α-MSH 1.8 19 9.9 10 5.5 
5 3-targeted polymer 26 -- -- -- -- 
6 3-targeted micelles 2.9 -- -- -- -- 
 
 Regarding therapeutics, targeted alpha-particle therapy (TAT) has been utilized with both 
peptides and antibodies as targeting agents and is an attractive option. The background of TAT is 
discussed at length in the introduction to this dissertation; in brief, the disintegrations of 
radioactive 225Ac produce a decay chain of daughter products and four total alpha particles (Figure 
2.1). These alpha particles have the mass of helium nuclei and when ejected from the nuclei at 
great velocities, have tremendous kinetic energy. When targeted to a tumor by peptide targeting of 
the overexpressed cell-membrane receptors, this cytotoxic alpha-emission can destroy localized 
tissues. 
   Analogous to the imaging work completed by Chen and Morse, the purpose of this 
research was to complex the cytotoxic radionuclide actinium-225 to an optimized version of the 
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MC1R Ligand (MC1RL).  In tandem with this targeted alpha-particle therapy goal, the promise of 
developing a companion imaging agent was tantalizing. The vision was to create a compound that 
could be complexed with an imaging radionuclide to assess susceptibility to TAT, a therapeutic 
radionuclide for TAT, and then repeated imaging to assess efficacy following treatment.  
Furthermore, by using a peptidomimetic as the targeting ligand, the pharmacokinetics, dynamics, 
and biodistribution could be optimized with simple modifications to the chemistry.  
 
Figure 2.1. Actinium-225 decay pathway. 
 
2.2 Results and Discussion 
 2.2.1 Peptide Design and Synthesis  
The linear MC1RL message sequence has previously been elucidated,18  with the C-
terminal lysine offering a branching point by utilizing an orthogonal allyloxycarbonyl (alloc) 
protecting group on its ɛ-amine. Not only was this branching critical for the inclusion of a payload 
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on the targeting ligand, it also helped facilitate efficient synthesis. Using this branching point, the 
targeting ligand was synthesized in larger batches (typically 0.1-0.5 mmol) up to the point of alloc 
deprotection. Different linkers and payloads were then appended in split syntheses.  Importantly, 
all of this synthesis was performed on solid support, yielding highly pure product in a manageable 
fashion.  Scheme 2.1 provides an overview of the solid phase peptide synthesis (SPPS) empolyed 
for this peptide and its analogs.  
 
 
Scheme 2.1. Typical solid phase peptide synthesis of linear MC1RL. 
 
 
Previously, the C-terminal branched lysine of this targeting ligand was coupled to a 
hexynoic acid monomer (Figure 2.1). This functional group enabled functionalization through so-
called ‘Click Chemistry22’ to large (91 nm) polymer micelles with and without texaphyrin-
gadolinium.21,23 Remarkably, the attachment of macromolecules did not disrupt the binding of the 
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peptide ligand with the extracellular receptor. The binding affinities of the parent peptide and 
polymer micelles were reported as 0.24 nM and 2.9 nM, respectively.18,21 The ligands also 
maintained their specificity for the MC1 isoform of the receptor.  It was inferred from these 
studies that the linker tethering the payload to the targeting peptide may have been important to 
retain high binding affinity for the receptor-target. 
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Figure 2.2. Structure of previously reported lead MC1RL targeting ligand.(Barkey, 2011)23 
 
To mimic the number of spacer atoms in the linker, the first MC1RL compounds for this 
project included a 6-aminohexanoic acid linker in place of the 5-hexynoic acid linker. The linker 
was both inexpensive and commercially available as the Fmoc-protected amino acid.  It was 
coupled using the same SPPS strategy with HCTU activation shown in Scheme 2.1. The MC1RL 
analog was then finished by attaching a DTPA metal-chelating motif to the aminohexanoic acid 
linker. After an acid cleavage, lyophilization, and subsequent HPLC purifications MC1RL-Ahx-
DTPA was isolated as a pure white powder.  This compound is shown Figure 2.3, R2.  
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This MC1RL-Ahx-DTPA compound was then complexed with europium and tested for 
binding affinity for the MC1R.  The Morse group ran this assay by testing direct peptide binding 
on whole-cells expressing the receptor.   The detection method for this experiment was release of 
europium from the complex, and the direct binding of the compound was measured at 1.3 nM 
(Kd).   
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Figure 2.3. Structures of MC1RL-Ahx-DOTA (R1) and MC1RL-Ahx-DTPA (R2). 
Having proved that a chelating molecule could be functionalized to the C-terminus of 
MC1RL, complexed with a lanthanide metal and still retain binding affinity, the next compound 
synthesized contained a DOTA motif.  This DOTA molecule would complex positive-three charge 
metals with tighter binding, and thus be more suitable for in vivo experiments. This second 
27 
 
MC1RL analog, MC1R-Ahx-DOTA (Figure 2.3, R1), was synthesized in an analogous fashion to 
the point of metal-chelator coupling. At this step, a tri-t-butyl-protected DOTA molecule was 
coupled to the C-terminal branch through an amide bond as shown in Schemes 2.1 and 2.2. 
Peptide was subsequently cleaved from the resin, and chromatographed to greater than 95% purity 
by reverse phase HPLC.  After lyophlization, the targeting ligand was isolated as a dry white 
powder in 29% overall yield (93 mg, 0.0631 mmol).  MALDI-TOF analysis determined the 
monoisotopic mass (M+H+) to be 1474.9036 (expected: 1474.7954). Table 2.2 lists other linear 
analogs, including MC1RL-Ahx-DTPA and MC1RL-Ahx-DOTA, which have been synthesized for 
this project. 
 
2.2.2 Chelation of Metals 
 Surrogate metal atoms were utilized for method development in place of radioactive 
radionuclides, our ultimate imaging and therapeutic agents.  Due to its oxidation state, size, and 
periodic table relationship, lanthanum was chosen as a surrogate for the alpha-particle emitting 
radionuclide, actinium-225.  The natural abundance isotopes of gallium (67/69) were an obvious 
substitute for the positron-emitting radionuclide, gallium-68.  Both of these surrogate metals were 
complexed with the purified MC1RL-Ahx-DOTA (Scheme 2.2). 
The complexation reaction was affected by stirring the pure DOTA compound with the 
three charge state chloride salt of each metal in 100 mM ammonium acetate, pH 8.   Initial 
experiments were carried out at room temperature with mechanical stirring.  The reaction was 
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monitored with analytical scale HPLC experiments using pH 6 buffered mobile phase buffer to 
slow the metal release from complexation.   
 
Table 2.2. Linear MC1RL analogs that have been synthesized and characterized by mass 
spectroscopy. 
Compound Formula Expected Mass (M+H+) Experimental Mass (M+H+) 
MC1RL C50H66N14O7 975.5312 975.5312 
MC1RL-Ahx-FBA C63H80N15O9F 1210.6320 1210.6185 
MC1RL-Ahx-DTPA C70H98N18O17 1463.7430 1463.7946 
MC1RL-Ahx-DTPA: Eu C70H95N18O17Eu 1610.6321 1610.6323 
MC1RL-Ahx-DOTA C72H103N19O15 1474.7954 1474.9038 
Scram.MC1RL-Ahx-DOTA* C72H103N19O15 1474.7954 1474.9086 
MC1RL(D5)-Ahx-DOTA C72H98D5N19O15 1479.8268 1479.9137 
MC1RL-Ahx-DOTA: La C72H100N19O15La 1610.6783 1610.6553 
MC1RL-Ahx-DOTA: Ga C72H100N19O15Ga 1540.6975 1540.6762 
MC1RL-Ahx-DOTA: Eu C72H100N19O15Eu 1624.6931 1624.8046 
MC1RL-Ahx-DOTA: In C72H100N19O15In 1586.6758 1586.6984 
MC1RL-diDGlu-DOTA* C76H106N20O20 1619.7965 1619.9089 
MC1RL-diDGlu-DOTA*: In C76H103N20O20In 1731.6769 1731.7107 
MC1RL-diDLys-DOTA* C78H116N22O16 1617.9012 1617.9916 
MC1RL-DOTA C66H92N18O14 1361.7113 1361.7437 
MC1RL-DOTA: La C66H89N18O14La 1497.5942 1497.6658 
MC1RL-DOTA: Ga C66H89N18O14Ga 1427.6134 1427.6444 
MC1RL-DOTA: Eu C66H89N18O14Eu 1511.6091 1511.7075 
MC1RL-DOTA: In C66H89N18O14In 1473.5917 1473.6042 
*denotes peptide ligand that was prepared by Dr. Hyunjoo Kill. 
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Scheme 2.2. Chelation of metals to Peptide Ligand-DOTA (shown with Ga+3). 
 
Figure 2.4 depicts the HPLC chromatograms from the reaction monitoring experiments. A 
time-zero, or pure peptide starting material, is shown for reference in box (a) with retention time of 
27 min.  After 2.5 h, the gallium reaction was shown to have progressed 80% (b) and was complete 
by 20 h.  The lanthanum chelation was shown to have fully progressed after only 4 h.   
A noteworthy observation of the metallated MC1RL peptides is their similar retention 
times from the HPLC experiments. Both the lanthanum- and gallium-bound compounds had 
retention times of 25 min using this method.  This similarity was a positive indication that the 
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metal bound peptides had similar physiochemical properties.  At this point our suspicion was that 
these similar properties would likely lead to similarly behaving compounds in terms of 
pharmacokinetics, pharmacodynamics, and biodistribution.   
 
 
Figure 2.4. HPLC chromatographic overlay comparing the time course of metal chelation with 
MC1RL-Ahx-DOTA. (a) Time-zero (0 h) run in the absence of metal showing a retention time of 
27 min for unchelated peptide. (b) Gallium chelation at 2.5 h showing both the metallated and 
the nonmetallated version of the peptide. (c) Gallium chelation at 20 h showing complete peptide 
chelation at ~25 m retention time. (d) Complete Lanthanum chelation (4 h) shown at 25 min 
retention time.  
 
 The next test of the surrogate-bound MC1R-Ahx-DOTA compounds was their binding 
affinity for the MC1R.  This assay was performed by the Morse lab in their competition-style time 
resolved fluorescence binding assay.24  Here a well-known and characterized ligand (NDP-α-MSH) 
with affinity for the melanocortin receptors was complexed with the lanthanide, europium. A 
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direct measurement of NDP-α-MSH binding to expressed melanocortin-1 receptors can be made 
down to the attomole ligand quantity. The test compounds were then allowed to compete with the 
europium compound to indirectly determine their binding affinity in the cell-based assay. Figure 
2.5 shows the binding curves for the unbound ligand and the gallium- and lanthanum- complexes.   
 
 
Figure 2.5. Whole-cell competition binding affinities of metallated and unmetallated MC1RL-Ahx-
DOTA analogs. Assay performed by Valerie Moberg.  
 
 The new MC1RL-Ahx-DOTA compounds were shown to bind with MC1R at similar sub-
nanomolar affinities to those previously reported in the literature. The Ki of the tested compounds 
were recorded as 0.24, 0.23, and 0.34 nM for the 139La-, 69/71Ga-, and the unbound- MC1RL-Ahx-
DOTA compounds respectively.   Once again, the similar binding affinities of the different 
surrogate chelates provided evidence that the compounds would behave similarly in vivo.   
 After having successfully labeled the MC1RL-Ahx-DOTA compound with the cold 
surrogate metals, the empty compound was sent to Wake Forest University for radiolabeling in the 
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lab of Dr. Thad Wadas.  That group has had expertise working with actinium-225 obtained from 
the Oak Ridge National Laboratory.  There, MC1RL-Ahx-DOTA was loaded with 225Ac under 
similar conditions to our own labeling procedure and then tested for radiochemical purity and 
plasma stability. The Wadas group labeled the compound in 95% radiolabeling yield and 99.8% 
radiochemical purity.  They also incubated (37 °C) the radiolabeled compound (56 µCi) in human 
serum and monitored radiochemical purity over the course of 10 days. They reported roughly 90% 
stability of the actinium-bound targeting ligand at the end of the time course.  
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Figure 2.6. Structure of scrambled-MC1RL-Ahx-DOTA. 
During this time another version of MC1RL was constructed by Dr. Hyunjoo Kil to be 
used as a non-binding control for the biological testing. This compound had the primary sequence 
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of the MC1RL pharmacophore mixed up, or scrambled, to eliminate specific binding to the 
melanocortin-1 receptor. Instead of the correct binding sequence (His-DPhe-Arg-Trp-Gly) the 
scrambled sequence was composed of amino acids in the order: Trp-Gly-His-Arg-DPhe.   Figure 2.6 
shows the structure of the completed scrambled-MC1RL-Ahx-DOTA.  Finally both MC1RL-Ahx-
DOTA:Ac and its scrambled control were shipped back to the Moffitt Cancer Center the Morse 
group’s testing of the compound in both in vitro and in vivo studies.   
 
2.2.3 Biological Testing of MC1RL Compounds 
The actinium-chelated targeting ligands, MC1RL-Ahx-DOTA:Ac  and its scrambled analog, 
were tested in a barrage of experiments. Dr. Narges Tafreshi led the group’s experimentation.  The 
radiolabeled compounds were tested for cytotoxicity by assaying melanocortin-1 receptor positive 
cells for metabolic activity after dosing with MC1RL-Ahx-DOTA:Ac (MTT assay). A maximum 
tolerated dose was examined in non-tumor bearing mice. At the time of this writing, efficacy 
studies had begun to test the MC1RL-Ahx-DOTA:Ac compound against controls of injected 
saline, the scrambled-MC1RL-Ahx-DOTA:Ac, and the cold lanthanum surrogate, MC1RL-Ahx-
DOTA:La.  
 Another test of the MC1RL-Ahx-DOTA:Ac compound was the determination of 
biodistribution in tumor bearing mice.  Work done by Dr. Tafreshi in the Morse group alongside 
the medical physicists in the Small Animal Imaging Laboratory (SAIL) at Moffitt produced the 
biodistribution (BD) graph in Figure 7. This data was gathered by counting gamma ray emission 
from actinium and radiodecay products in the listed organs and tumors.  A valuable output from 
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this study is the differential uptake in tumors expressing either high or low levels of engineered 
MC1R.  Tumors with higher levels of receptor expression were shown to have substantially more 
uptake of targeting ligand.   
 
Figure 2.7. Biodistribution of MC1RL-Ahx-DOTA:Ac in tumor bearing mice. BD experiments 
performed by Drs. Tafreshi and Budzevich.   
 
 
 Another striking feature of this BD study was the amount of actinium uptake in the 
metabolic organs. Both the liver and kidneys showed increased uptake over the other tissues.  Liver 
uptake was of special concern since it had the highest uptake of any tissue, tumor-bearing or not.  
Tolerable doses of hepatic and renal radiation, particularly to patients receiving treatment for 
potentially fatal diseases, is currently unknown. However, a medicinal chemistry solution to this 
off-target uptake would be particularly helpful.   
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Figure 2.8. Structure of MC1RL-IR800CW.25 
 A previous version of MC1RL with a fluorescent dye payload was published in 2012 by 
collaboration of the Morse and Vagner groups at the University of Arizona.25  The compound 
(shown in Figure 2.8) reported in this publication featured and IR800CW fluorescent dye coupled 
to the same binding sequence used in our MC1RL.  This dye includes 4 sulfonate functional 
groups appended to its structure to aide in the solubility of the hydrophobic dye.  Importantly, this 
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targeted imaging agent was shown to target MC1R expressing tumors in mice while avoiding 
hepatic uptake.    
 
2.2.4. Biodistribution Modulation  
Surveying the differences in the MC1RL targeting ligands with DOTA and with the 
IR800CW dye (Figure 2.8), a disparity in lipophilicity is perceived.  The fluorescent dye payload 
should have a negative-three formal charge at physiological pH. In contrast, all of our DOTA 
compounds with complexed metals should retain neutral payloads at physiologic pH.  Therefore a 
hypothesis was put forward that altering the lipophilicity of the MC1RL payloads could attenuate 
uptake in off-target organs such as the liver.   
 To this end, several MC1RL DOTA analogs were synthesized. The plan for this medicinal 
chemistry project was that hydrophilic linkers could be designed to tether the DOTA payload by 
either eliminating the 6-aminohexanoic acid linker or by adding ionizable groups, analogous to the 
sulfonates in the IR800CW compound. Then the lipophilicity of the new constructs could be 
measured using conventional experimental methods. Finally the MC1RL analogs could be 
complexed with radionuclides suitable for imaging, and the in vivo distribution of these new 
compounds could be determined.   
Three new compounds were prepared for this study with the help of Dr. Hyunjoo Kil and 
are depicted in Figure 2.9. The first analog was the result of simply omitting the 6-aminohexanoic 
acid linker. By eliminating this original linker between MC1RL and DOTA, the aim was to 
increase hydrophilicity by reducing the number of methylene groups.  Two other compounds were 
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designed with either two glutamate residues or two lysine residues in place of the aminohexanoic 
acid linker.  These residues would each impart 2 formal charges to the MC1RL payload at 
physiologic pH while maintaining a similar linear spacing of atoms between the targeting ligand 
the DOTA.  The inserted amino acids were included as the D- configuration to help promote 
proteolytic stability.   
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Figure 2.9. MC1RL analogs synthesized to modulate lipophilicity. 
 With the new MC1RL compounds synthesized, the next step was to test their respective 
lipophilicities.  A simple lipophilicity experiment was conducted by partitioning each individual 
compound between PBS (pH 7.4) and octanol. Next the concentrations of ligand in each layer 
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were determined from a LC-MS/MS method and the LogD7.4 of each analog was calculated. A 
graph of the results of these lipophilicity experiments is included as Figure 2.10.   
 
 
Figure 2.10. Graphical display of experimentally determined LogD7.4 for MC1RL analogs. 
Compound MC1RL-IR800CW was assayed for LogD7.4  in Tafreshi et al.
25 
 
 Six MC1RL analogs were assayed for LogD7.4 in this study and plotted in Figure 2.10. The 
MC1RL-IR800CW compound from Tafreshi et al25 is also listed with its value of -3.10 ± 0.13.  
Briefly, compounds with more negative values are understood to be more hydrophilic.  The 
impetus to create these analogs was to get close to the MC1RL-IR800CW lipophilicity.  Our 
standard compound, Mc1RL-Ahx-DOTA, was measured at 2.02 ± 0.07. Removing the 6-
aminohexanoic acid linker actually increased the lipophilicity to 1.79 ± 0.03.  Adding the di-
glutamate or di-lysine linkers resulted in compounds measured at -2.58 ± 0.17 and -2.56 ± 0.22 
respectively.  Interestingly, complexation of the cold surrogate lanthanum with MC1RL-Ahx-
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DOTA dropped the LogD7.4 over half a logarithm to -2.59 ± 0.20. Extrapolating this change to 
either the di-glutamate or di-lysine compounds would result in a compound with strikingly similar 
lipophilicity to the MC1RL-IR800CW compound.   
 Next, two MC1RL analogs (MC1RL-Ahx-DOTA and MC1RL-diDGlu-DOTA) were 
complexed with indium-111 in order to determine their biodistribution in mice by SPECT 
imaging.  Reference compounds with natural abundance In-113 were complexed in 100 mM 
sodium acetate (pH 5.55) with heating to 70 °C.  These reference compounds were used by Dr. 
Haibin Tian’s Radiochemistry lab in the complexation of the same precursor MC1RL compounds 
with ‘hot’ indium-111.  The protocol for the hot synthesis was modified by using 100 mM HEPES 
buffer (pH 5.5) to reduce the competition of the cadmium daughter product.26  These radiolabeled 
compounds were again tested by Drs. Tafreshi and Budzevich in the small animal imaging lab at 
Moffitt.  
 Figure 2.11 shows the biodistribution in mice of two MC1RL analogs from their SPECT 
images.  The distribution of the peptide with the 6-aminohexanoic acid linker (left) has the highest 
absorption by the liver, with kidney uptake as the second highest organ. Other organs accounted 
for very little intensity.  By changing the linker from Ahx to the two D-glutamate residues, the 
distribution between the liver and kidneys flip-flopped.  The MC1RL-diDGlu-DOTA:In 
compound (Figure 2.11, right) had the highest uptake in the kidneys and very little uptake in the 
other organs, including the liver. This remarkable result correlates well with the prediction from 
the lipophilicity studies.  In essence, by including a linker that decreased lipophilicity, the 
compound behaved like previously published analogs that were initially observed to avoid liver 
uptake.  
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Figure 2.11. Biodistribution of indium-111 labeled MC1RL analogs.  
 
2.2.5 Constrained MC1RL Variants  
Constraining peptide ligand conformation is a practice that has long been used to 
investigate structure-activity relationships, probe the relationship of agonists and antagonists, 
increase proteolytic stability, and enhance potency. Due to the degree of flexibility and permissible 
dihedral angles, unrestrained peptide sequences can sample a large amount of chemical space.27  
Macrocyclization and the introduction of bulky amino acid monomers may result in rigidifying the 
peptide ligand backbone.28,29 When properly screened, a rigid conformer may be found with 
increased affinity for its target since it has less chemical space to sample for the most correct 
conformations.30,31  These more rigid structures also typically exhibit qualities of increased 
proteolytic stability and increased circulatory half-lives due to their ability to appear less peptide-
like to proteolytic enzymes.   
The evolution of constrained melanotropin analogs dates back to the 1980s when Tomi 
Sawyer et al. published their work constraining an analog of α-MSH.32 Their new peptide was the 
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result of two point mutations (p.M4C and p.G10C) in the endogenous tridecapeptide sequence, 
Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-CONH2. These isosteric substitutions 
allowed for oxidative macrocyclization through disulfide formation.  The resulting constrained 
peptide was termed [half-Cys4,half-Cys10]α –MSH and is shown in Figure 2.12.  The blue section of 
this peptide is the so-called ‘message sequence,’ responsible for binding to the melanocortin 
receptor.  
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Figure 2.12. Structure of [half-Cys4,half-Cys10]α –MSH.32 
The authors of this paper based their rationale for constraining the linear peptide around 
their previous discovery of the effect of a D-phenylalanine substitution on the native L-
phenylalanine in position-7.  This point mutation was suggested to stabilize a reverse β-turn in the 
message sequence.31 Substituting in the D-configured amino acid in the linear message sequence 
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resulted in 10,000 times more potency in their frog skin activity assay. However this compound 
lacked the necessary selectivity for the MC1R. 
Continued research by the same group, and under the direction of Dr. Victor Hruby, led 
them to another cyclic peptidomimetic named melanotan-II (MT-II).33,34  This melanotropin analog 
was constrained by a lactam bridge and maintained the critical ‘message sequence’ pharmacophore 
from α-MSH (see Figure 2.13). This compound went to phase I clinical trials under the claim that 
it would darken skin pigmentation in an effort to avoid melanomas. However, due to selectivity 
issues for other isoforms of melanocortin receptor, it was never approved for human use beyond 
its clinical trial.   
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Figure 2.13. Structure of MT-II (melanotan-II).33,34 
 The current research with constrained melanotropins took these previous macrocyclic 
peptidomimetics into consideration, and expanded upon previous lab member’s work of creating 
β-hairpin turn peptides.  A goal of this work was to develop a more stable ligand, and possibly an 
antagonist. The conceptualization of our design is shown in Scheme 2.3. The scheme is color 
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coded to guide the viewer through the thought process of bending the peptidomimetic backbone 
around the β-turn promoted by the D-phenylalanine. The other elements from our MC1RL 
‘message sequence’ remain present through the turn, which is held together both through 
hydrogen bonding of the antiparallel β-sheet-like motif and a D-proline inspired turn on the 
opposite side.  
H
N
N
H
H
N
N
H
H
N
NH2
O
O
O
O
O
N
H O
O
NHN
NH
HN NH2
NH
HN
R1
CO
H
N
NH
O
N
O
H
N
H
O
n
N
H
O H
N
O
O
NH2
NHR1
N
HN
NH
NH2
HN NH
CO
H
N
NH
O
N
O
H
N
H
O
n
N
O
N
HN
NH
NH2
HN NH
HN
CO
A
B C  
Scheme 2.3.  Constraining linear MC1RL around the turn promotion region. 
Since the 4-phenylbutyric acid was shown to be important for selectivity,14,15 it was 
envisioned that a phenylalanine homolog could be incorporated to both maintain the phenyl ring 
and allow for the new amide bond necessary for head-to-tail macrocyclization. However the new 
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amino acid would set another chiral center and the correct epimer would have to be determined. 
The phenylalanine homolog would also introduce the opportunity to tune the number of 
methylene groups between the N-terminus and the phenyl ring.  As such, structure-activity 
relationships were compared from the inclusion of four homologs: D- and L- homophenylalanine 
and phenylalanine. The macrocycles were closed through a C-terminal D-proline which formed an 
amide bond with the N-terminal phenylalanine homolog.  
Scheme 2.4 lays out the synthesis of each constrained MC1RL analog.  Product loss to 
diketopiperizine formation was observed with proline-loaded Wang resin as solid support. The 
bulkier chlorotrityl resin was substituted. Conventional Nα-Fmoc strategy SPPS with HCTU 
activation was employed to couple D-Pro, Trp(Boc), Arg(Pbf), D-Phe, and His(Trt). At this step in 
the synthesis the resin was split four ways to allow for the variable position of either D- or L- 
homophenylalanine or phenylalanine.   
 Finally each of the four resin-bound variants were split to accommodate linear and cyclic 
variations of each ligand.  Resin for the linear products was cleaved with a cocktail of TFA, TIS, 
and H2O (95:2.5:2.5, v/v).  Resin for cyclization was cleaved from solid support with protecting 
groups intact by AcOH:TFE:DCM (2:2:6 v/v).  By maintaining the protecting groups on this 
subset of analogs, a solution phase cyclization step was done through propylphosphonic anhydride 
(T3P) condensation.  Finally the protecting groups were removed by treatment with TFA cocktail.   
The eight MC1RL variants were completed and sent to Dr. Tafreshi in the Morse group to 
determine binding affinity and functionality. Figure 2.14 lists a table (C) comparing the results 
from these assays.  All compounds were synthesized in acceptable crude yields (32-84%) and the 
mass spectra confirmed their identities.  The compounds with the tightest binding affinity for the 
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MC1R were the analogs with L-homophenylalanine.  Both the linear and cyclic analogs with this 
amino acid achieved single digit binding affinity, Ki of 2.2 nM and 6.5 nM respectively.  
 
 
Scheme 2.4. Constrained MC1RL Synthesis.  
The lead compounds based on binding affinity were then put into a functional assay by Dr. 
Tafreshi.  In the first pass, compound B54 cyclic exhibited antagonistic behavior compared to the 
controls and compounds B53 linear and cyclic.  However, repeating the experiment yielded 
ambiguous results. The activity directed by receptor binding of the constrained compounds 
remains unknown.  
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Figure 2.14.  Summary of constrained MC1RL compounds. A) Generalized structure of 
constrained MC1RLs. The blue line denotes the amide bond present in the fully cyclic structure or 
where the macrocyclic ring would be open for the linear variants.  The red circle shows a generic 
phenylalanine homolog.  B) Representative HPLC chromatogram of cyclic MC1RL. C) Table of 
synthesized compounds listing yields, mass spectral summaries, binding affinities, and sequence 
information.   
 
 
 
 
2.3 Conclusions 
 The melanocortin-1 receptor is a valuable cell-surface marker which characterizes a large 
percentage of uveal and cutaneous melanomas.  This protein receptor can be successfully targeted 
with peptidomimetics derived from the endogenous peptide hormone, α-MSH.  Further 
manipulations of the peptidomimetic have resulted in peptide ligands with high binding affinity 
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and selectivity, which can be altered to carry payloads of metal chelating molecules. By taking 
advantage of various radioactive elements in these peptide ligand complexes, companion imaging 
and therapeutic peptide targeting ligands have been synthesized.  
 Complexes of targeting ligands with lanthanum-139, gallium-67/69, and indium-113 have 
been synthesized which can act as surrogates to help inform about physiochemical behavior of 
their radioactive complements.  Radioactive indium-111 has been successfully complexed to track 
the biodistribution of compounds through SPECT imaging. Further peptidomimetics have been 
constructed, and also take advantage of SPECT, to explore the connection of linker lipophilicity 
with biodistribution. These analogs have successfully altered metabolic organ uptake.  Finally, 
actinium-225 complexes of peptide targeting ligands have demonstrated the successes of TAT 
therapy. Initial efficacy studies showed a complete tumor loss in 22% of treated animals, which 
resulted in significantly longer survival.   When compared with analogous TAT using antibodies, 
the peptide-based targeting ligands result in a more proper balance of radioactive half-life, 
pharmacokinetics, and biodistribution of the therapeutic agent. 
 In addition to the linear MC1RLs, constrained peptidomimetics have also been 
synthesized. These new constructs retain the high binding affinity for the MC1R and may serve as 
antagonists.  A true antagonistic melanotropin would be the first of its kind. This type of molecule 
could be used as a dedicated imaging agent or otherwise where receptor activation and 
internalization could result in deleterious effects.  Further work on this class of cyclic 
melanotropin analogs is necessary to add tethers for payload attachment but the proof of concept 
for these compounds is promising.  
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2.4 Experimental  
2.4.1 Materials and Instrumentation 
All purchased solvents and reagents were obtained at ACS grade or higher purity level and 
used without further purification unless specified otherwise. Peptide coupling reagents and amino 
acids were obtained from either Chem-Impex, Novabiochem or Advanced ChemTech.  Distilled 
NMP (99.96%) was purchased from Chem-Impex.  Tentagel Resin was obtained from Rapp 
Polymere.  HPLC grade Acetonitrile was purchased from or Fisher was used for HPLC and de-
ionized water was processed by Millipore Milli-Q water purifier for HPLC. 
Amino acids with the following configurations were purchased from ChemImpex: Fmoc-
Lys(Alloc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-D-Phe-OH, Fmoc-His(Trt)-OH, and 
Fmoc-6-Aminohexanoic Acid. CDN Isotopes provided the Fmoc-D-Phe(D5)-OH. Tri-t-butyl-
protected DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid) was purchased from 
TCI America (Portland, Oregon). DTPA (diethylenetriaminepentaacetic acid), bought as the 
dianhydride (DTPAA), and 4-phenylbutyric acid was purchased from Sigma-Aldrich.  
A Varian solvent delivery module with Dionex UVD340U diode array detector was used 
for preparative HPLC chromatography.  Analytical scale HPLC was performed using either a 
Dionex P680 system or an Agilent 1200 system, both with quaternary pumps, autosamplers, and 
diode array detectors.  Mass spectral analysis was performed with either Agilent 6540 QTOF  with 
dual Jet-Stream ESI source coupled to Agilent 1260 Infinity HPLC, Agilent 6460 QQQ  with Jet-
Stream ESI source coupled to Agilent 1260 Infinity HPLC, Agilent LC/MSD VL single 
quadrupole with Agilent 1100 series HPLC, or Applied Biosystem 4700 MALDI-TOF-TOF 
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proteomics analyzer with 355nm Nd:YAG laser. Peptides were lyophilized on a Labconco Freeze 
Dry/Shell Freeze System.   
 
2.4.2 Experimental Procedures 
2.4.2.1 Linear MC1RL Synthesis. MC1RL peptide was synthesized according to 
conventional Nα-Fmoc peptide synthesis strategy using HCTU/NMM or DCC for monomer 
activation and coupling (Scheme 1).  A glass-fritted peptide reaction vessel was charged with 2 g 
TentaGel Rink amide resin (0.23 mmol/g, 0.46 mmol) and swollen with DCM (2x 20 mL) 
followed by NMP (3x 20 mL).  The resin was agitated by bubbling with N2 gas from the bottom 
glass frit and drained from vacuum filtration on the frit. Next the resin-bound Fmoc was 
deprotected with a mixture of 20% piperidine, 2% DBU in NMP (15 mL, 15 min, 2x).  Following 
deprotection, the resin wash step was accomplished through resin agitation followed by complete 
drainage with a sequence of washes: NMP (15 mL, 3x), DCM (15 mL, 3x), and NMP (15 mL, 3x).  
Next the preactivated amino acid monomer was incorporated as the HCTU ester.  The first amino 
acid, Fmoc-Lys(Alloc)-OH (5 eq) was weighed into a flask with HCTU (5 eq), NMM (15 eq) and 
dissolved to 0.2 M in NMP.  This coupling cocktail was allowed to preactivate at rt for 10 min, and 
was then added to the resin for coupling with agitation for 1 h.  After coupling, the resin was 
drained, washed as before, and assayed for reaction completeness by Kaiser test. The cycle of Fmoc 
deprotection, washing and coupling was repeated with Fmoc-Gly-OH, Fmoc-Trp(Boc)-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-D-Phe-OH, Fmoc-His(Trt)-OH, and capped with 4-phenylbutyric acid.  
Qualitative Kaiser assay at the Trp, Arg, and Phe positions revealed  incomplete coupling so an 
additional step of preparing the symmetric anhydride with the amino acid (4 eq) and DCC (2 eq) 
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was performed by warming (40 °C) the monomer/DCC in DCM for 30 min. The urea byproduct 
was filtered from the anhydride and filtrate added directly to the already bubbling (10 mL NMP) 
resin.   This coupling reaction was allowed to proceed for an additional hour.   
Other linear MC1RL analogs were synthesized by analogous technique, substituting the 
appropriate amino acid acids in the proper order. For instance, the scrambled sequence 
(synthesized by Dr. Hyunjoo Kil) incorporated monomers in the following order: Fmoc-Lys(Alloc)-
OH, Fmoc-D-Phe-OH, Fmoc-Arg(Pbf)-OH, Fmoc-His(Trt)-OH, Fmoc-Gly-OH, Fmoc-Trp(Boc)-OH, 
4-phenylbutryic acid.  Another MC1RL analog with 5 deuteriums was synthesized by substituting 
Fmoc-D-Phe(D5)-OH.  This analog was used as in internal standard for the QQQ mass 
spectroscopy measurements.   
 
2.4.2.2 Alloc Deprotection. After completion of the linear portion of the targeting ligand, 
the molecule was branched from its C-terminal lysine by deprotection of the orthogonal Alloc 
group on the ɛ-amine.   The resin was bubbled in DCM (15 mL) with catalytic Pd(0)(PPh3)4 (5 
mol%) and 5 drops of piperidine for 1 hour.  Kaiser test and a small test cleavage for MALDI-TOF 
confirmed the complete deprotection.  Resin washes followed in the typical procedure after washes 
(15 mL, 2x) with 5 mol% sodium diethyldithiocarbamate in NMP and 10% DIEA.  
 
2.4.2.3 Peptide Branching, Linkers, and Payloads. After alloc deprotection, payloads were 
coupled at the C-terminus through the free ɛ-amine.  When linkers such as Fmoc-6-aminohexanoic 
acid (Ahx), di-Fmoc-D-Lys(Boc)-OH, and di-Fmoc-D-Glu(OtBu)-OH were incorporated, they were 
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added using typical cycles of washing, Fmoc deprotection, and coupling (5 eq monomer, 5 eq 
HCTU, 15 eq NMM in NMP).   
 Payloads such as DOTA and 4-fluorobenzoic acid (FBA, a reference compound prepared 
for use in the radiochemistry lab) were also coupled with typical preactivation (5 eq monomer, 5 eq 
HCTU, 15 eq NMM in NMP).  Diethylenetriaminepentaacetic dianhydride (DTPAA) was coupled 
by acyl chloride activation with triphosgene. Triphosgene (bis(trichloromethyl) carbonate (211 mg, 
0.712 mmol)) and  DTPAA (763 mg, 2.14 mmol) were weighed into a scintillation vial.  DIEA 
(0.75 mL, 4.3 mmol) and 10 mL of NMP were and added to the scintillation vial and the 
preactivation reaction was shaken for 30 minutes before being added to the peptide reaction 
vessel.  The coupling reaction was agitated for 2 hours, drained and washed with the following 
solvents (15 mL each): NMP, THF, 20% THF (aq.), 10% DIEA/10 % H2O in THF, 20% THF 
(aq.), THF,  DCM.35 
 
2.4.2.4 Peptide Cleavage, Lyophilization, and Purification. Following the completion of 
peptide synthesis, resin was washed with DCM (15 mL, 2x) and dried under a stream of N2 gas. 
The dried resin was agitated with cleavage cocktail (10 mL/g resin) of TFA, diH2O, TIS 
(95:2.5:2.5, v/v) for 3 hours at rt.  The acid was filtered from the resin, reduced to a thick oil 
under a stream of N2, and precipitated with 20 mL ice cold diethyl ether.  The precipitate was 
centrifuged for 5 minutes at 4,000 rpm and the ether was decanted.  Ten milliliters of cold ether 
was added to the crude peptide precipitate and the slurry was again spun and decanted twice more.  
Finally the crude peptide pellet was reconstituted in H2O, frozen and lyophilized to yield off-white, 
crude powder.   
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Crude peptide was characterized by analytical scale HPLC utilizing an AAPPTEC Spirit 
Peptide column (C18, 5µm, 25x0.46cm).  UV detection was monitored at 222 nm and 254 nm.  
Mobile phase (A: H2O + 0.1 % TFA, B: ACN + 0.1 % TFA) was pumped 1 mL/min with the 
following gradient: 2 % B for 3 min to load the samples then 20-40 % B over 20 min, then the 
column was washed at 95 % and re-equilibrated at 2 % B for the next HPLC experiment.  
For purification, crude peptide was chromatographed on an AAPPTEC Spirit Peptide 120 
column (C18, 5 µm 25x2.12 cm).  The UV detection was monitored at 222 nm.  Mobile phase (A: 
H2O + 0.1 % TFA, B: ACN + 0.1 % TFA) was pumped at 15 mL/min with the following gradient: 
5 % B for 10 min to load the samples followed by a linear gradient of 20-25 % B over 50 min for 
separation.  Fractions were collected by hand, analyzed by both analytical HPLC and MALDI-TOF.  
Fractions with purity greater than 95 % were pooled, frozen and lyophilized.   
 
2.4.2.5 Mass Spectrometry Characterization: MALDI-TOF and QToF. MALDI -TOF and 
-TOF/TOF experiments were used to analyze both crude and pure peptides. Samples were 
premixed 1:1 (v/v) with a saturated solution of α-cyano-4-hydroxycinnamic acid and then 500 nL 
was spotted on the MALDI plate.   Unless otherwise specified, the instrument was run in positive, 
reflective mode. For MS/MS experiments Precursor ions were selected after analysis of reflective-
mode TOF measurement from 1000-2000 m/z.  
For QToF characterization of purified peptides, the samples were introduced to the mass 
spectrometer as a direct infusion from the HPLC.  The instrument was set to high resolution 
mode in extended dynamic range.  Typically, only positive polarity was measured. Real-time 
reference masses were infused in the second nebulizer during the acquisition.   
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Figure 2.15.  QToF analysis of gallium-chelated MC1RL-Ahx-DOTA.  The main spectrum shows 
the m/z range from 300-1800, covering the M+ H+, 2H+, and 3H+ species.  The inset spectrum 
highlights the isotope window around the M+H+ species.    
 
 Figure 2.16.  QToF analysis of lanthanum-chelated MC1RL-Ahx-DOTA.  The main spectrum 
shows the m/z range from 400-2000, covering the M+ H+, 2H+, and 3H+ species.  The inset 
spectrum highlights the isotope window around the M+H+ species.    
 
For QToF characterization of purified peptides, the samples were introduced to the mass 
spectrometer as a direct infusion from the HPLC.  The instrument was set to high resolution 
mode in extended dynamic range.  Typically, only positive polarity was measured. Real-time 
reference masses were infused in the second nebulizer during the acquisition.   
Figures 2.15 and 2.16 are representative QToF specta for both the gallium-chelated and 
lanthanum-chelated MC1RL-Ahx-DOTA peptides, respectively. The red boxes depict a predicted 
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isotope pattern (showing both predicted intensity and spacing), and the black lines are the actual 
subtracted, centroid measurements. The M+H+ measurement for Ga-peptide of 1542.6936  m/z is -
3.6 ppm (calculated m/z: 1542.6991). The M+H+ measurement for La-peptide of 1610.6628 m/z is 
-9.6 ppm (calculated m/z: 1610.6783).  No un-chelated peptide was detected by QToF in ether Ga- 
or La- complexed samples.  Mass spectral measurements for the other compounds are listed in 
Table 2.2 and spectra are shown in the appendix. 
 
2.4.2.6 Metal Chelation 
2.4.2.6.1 Europium chelation. Peptide with DTPA ligand was dissolved in slightly basic 
ammonium acetate buffer (pH 8) to form the tetra-carboxylate compounds.  Three equivalents of 
europium chloride hexahydrate were added and the resulting clear and colorless solution was 
stirred at rt.  It was anticipated that the degree of chelation could be monitored by analytical 
HPLC, so aliquots were taken at time zero (before Eu), 16 h, and 40 h and chromatographed on 
the pH 6 HPLC method (A: H2O + 0.1 % TEA/AcOH, B: 90 % ACN 10 % phase A adjusted to 
pH 6 with AcOH).  No shift in retention time was noticed but the m/z corresponding to Eu 
chelated product was shown on QTOF LCMS without any starting peptide.  The peptide solution 
was subsequently frozen and lyophilized.   The resulting powder was passed through the 
preparative HPLC system once more under the pH 6 method and the product peaks were 
lyophilized to yield the final product. 
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2.4.2.6.2 Gallium-67/69 and lanthanum-139 chelation. MC1RL-Peptide with DOTA was 
dissolved in 0.1 M ammonium acetate (pH 8) at 5 mg/mL to form the tri-carboxylate compound.  
Three equivalents of each metal (Gallium (III) Chloride or Lanthanum (III) Chloride) were added 
and the resulting clear and colorless solution was stirred at room temperature.  Reaction 
monitoring of the chelation progress was done with the pH 6 HPLC method to avoid carboxylate 
protonation and loss of chelation.   
 
2.4.2.6.3 Indium-113 reference compounds. Peptides dissolved in 100 mM sodium acetate, pH 
5.55 at 3 mg/mL.  Three equivalents of InCl3*4H2O were added to each reaction and stirred at 
70 °C.  Reactions were monitored at 20 min by analytical HPLC, and all had complete shifts in 
retention time by 5 min  Finally 5 mM EDTA was added to each reaction and upon clearing the 
reaction solutions were chromatographed on the semi-preparative HPLC system. Gradients of 
acetonitrile and water with 0.1 % TFA were used to isolate the purified products which were 
subsequently lyophilized to white powder.   
 
2.4.2.7 Constrained Peptide Synthesis. After drying overnight under high vacuum, 1 g of 
2-chlorotrityl chloride resin (1 .49 mmol) was loaded with Fmoc-D-Pro-OH (1.5 eq) by mixing with 
dry DCM (20 mL) and DIEA (6 eq).  The resin was agitated by nitrogen bubbling at rt for 2 h.  
Next the resin was washed 3x each with DCM/MeOH/DIEA (17:2:1, v/v), DCM, NMP, DCM 
and the resin was dried under high vacuum overnight. The Fmoc- loading was measured by 
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quantitative 290 nm absorbance measurements of dibenzofulvene upon microscale (1 mg resin) 
deprotection with 20% piperidine in DMF.  Loading was calculated to be 0.32 mmol/g.   
The following amino acids were coupled with the same SPPS strategy as outlined in the 
linear MC1RL section: Fmoc-Trp(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-D-Phe-OH, Fmoc-His(Trt)-
OH.  At this stage the resin was spit to four equal portions.  Each portion had a distinguishing 
phenylalanine homolog coupled.  The monomers Fmoc-Phe-OH, Fmoc-D-Phe-OH, Fmoc-
HomoPhe-OH, and Fmoc-D-HomoPhe-OH were used as homologs.   
Each of the four portions of resin was split once more to produce the linear and cyclic 
variants.  The linear peptides were cleaved in the usual manner with a cocktail of TFA, H2O, TIS 
(95:2.5:2.5 v/v), precipitated in cold diethyl ether, and lyophilized.  The remaining resin had its 
peptide cleaved from solid support with AcOH, TFE, DCM (2:2:6) for 2 h at rt.  The mixture was 
filtered and reduced in vacuo, yielding thin yellow oil.  The compounds were then cyclized by 
dissolving the oil in dry DCM with DIEA (2.5 eq) and 2 equivalents of propylphosphonic 
anhydride (50 % in methyl THF).  The cyclization reactions were mixed by mechanical stirring 
overnight under dry N2 gas.  The reactions were quenched with 10 mL H2O, and the organic layer 
separated and reduced under vacuum. Finally the cyclized peptides had protecting groups removed 
by treatment with TFA cocktail and worked up in the usual manner. 
 
2.4.2.8 Lipophilicity Measurements. Prior to performing the lipophilicity experiments, a 
triple quadrupole MRM method was developed to measure unknown quantities of MC1RL 
analogs with high specificity and sensitivity. The method used M+3H+ charge state precursor ions 
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for all analogs (examples shown in Figures 2.15 and 2.16). Two transitions for each analog were 
monitored and optimized in the MRM method.  Figure 2.17 depicts the structure of the MC1RL-
Ahx-DOTA:La transitions. Since the transitions are characteristic of each peptide structure, each 
method was specific for the particular analog.  The most abundant product ion observed was the 
result of histidine side cleavage yielding the imidazole immonium ion (m/z = 110).  A second 
highly abundant, and very specific, product ion was the two charge state immonium product of a 
b-type amide bond cleavage.36  An example of a product ion scan for MC1RL-Ahx-DOTA:La is 
shown in Figure 2.18. 
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Figure 2.17. MRM transitions developed for MC1R-Ahx-DOTA:La.   
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Figure 2.18. Product ion scan for MC1RL-Ahx-DOTA:La with precursor selected as 537.55 m/z. 
 
Once the transitions had been mapped, they were optimized to produce the highest 
abundances possible.  Fragmentor voltages were ramped from 50-225 V while monitoring the 
relative abundance of precursor ions. Analogously, collision energies were ramped 5-70 eV and the 
corresponding product ions were recorded.  Figure 2.19 shows the results of these optimization 
experiments.   
Next, a standard curve for each peptide was created.  Stock solutions were serially diluted 
from 25 µM to 8 nM and run through the method. Ten microliters of each standard was 
chromatographed by linear gradient of acetonitrile and water with 0.1 % FA. The eluent was fed to 
the mass spectrometer where the MRM method summed the specified transitions for each peptide.   
The transitions for each concentration point were summed, plotted, and a linear regression fit to 
the data to produce the standard curve for each compound.   
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Figure 2.19. Fragmentor voltage (A) and collision energy (B) optimization experiments for the 
MRM method.  
 
After the standard curves were created, the miniature shake flask method was used to 
determine the lipophilicity of each compound.  Stock solutions of peptide (200 µM) in 25 mM, pH 
7.4 phosphate buffer were prepared. Aliquots of the stock solutions were vortexed with three ratios 
of n-octanol.  The resulting emulsions were separated by centrifugation. Triplicate measurements 
of ligand concentration in each layer were used to calculate a LogD7.4. 
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CHAPTER THREE: 
SYNTHESIS OF A TOLL-LIKE RECEPTOR 2 FLUORESCENT ANTAGONIST FOR USE 
IN INTRAOPERATIVE GUIDED SURGERY 
 
3.1 Introduction 
While pancreatic cancer is not the most frequently diagnosed cancer (53,000 new cases in 
2016, US figure), it is one of the most deadly with 1 and 5 year survival rates of only 29% and 
7%.1 These low survival statistics are due in large part to poor diagnostic tools and a lack of 
targeted therapies. Surgical resection remains one of the most effective options for early stage 
treatment, but complete resection is often difficult due to local and distal metastases.2 Further, 
complete resection of the tumors, leaving clean margins have the best prognosis.3  
Toll-like receptors are type 1 transmembrane glycoproteins of which there are greater than 
10 isotypes known.4 Toll-like Receptor 2 (TLR2) is endogenously expressed primarily on the 
surface of immune cells, and has a role in the recognition of bacterial invaders.5  The receptor 
recognizes pathogen-associated molecular patterns (PAMPs) like those of the lipoprotein 
components of bacterial cell walls. The molecular recognition of these ligands causes a 
heterodimerization with either TLR1 or TLR6 which results in an intracellular signaling cascade.  
An end product of TLR2 receptor activation is the release of proinflammatory cytokines, 
commencing the host defense of the innate immune system.    
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At the Moffitt Cancer Center, Dr. David Morse’s group has previously confirmed high 
levels of expression of the receptor on pancreatic adenocarcinomas (70%) through tumor micro 
arrays and immunohistochemical staining.6 The receptor was not found in normal pancreas 
tissues. It was therefore determined that the receptor could be a valuable extracellular target of the 
disease. In collaboration with researchers in Arizona, a fluorescently-labeled peptide probe for 
TLR2 was developed.7 This compound is shown in Figure 3.1. The main features include 
dipalmitoylated cysteine, glycine, and D-serine in the pharmacophore, oligomeric PEG linkers 
flanking the pharmacophore, and a near infrared fluorescent dye (IR 800CW) coupled to the 
ligand’s N-terminus. Unfortunately the bioactivity of this agonist ligand was regarded as a liability 
for its use as an imaging agent.   
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Figure 3.1. Diacyl-TLR2L-IR800CW.7 
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Because of TLR2’s role in immune system signaling, it has become a target for 
immunotherapy and anti-inflammatory therapy.  Recently small molecule libraries and natural 
product libraries have been screened in order to find inhibitors for TLR2.8-11 Additionally, vaccine 
adjuvants have been designed as TLR agonists to increase the potency of peptide vaccines.12 Other 
studies have designed monoclonal antibodies to blockade TLR2 and have been shown to inhibit 
several cancers including breast, lung, colorectal, head and neck squamous cell carcinomas.13 
Finally, peptide-based agonists have been designed to mimic exogenous lipoproteins from 
microbial cell walls through the inclusion of fatty acids.14,15 None of these reported peptide ligands 
have been potent antagonists or have been conjugated with fluorescent dyes. However, SAR work 
has been reported in which the simplification of the pharmacophore led to modulation of receptor 
binding effects.16,17 From the review of these studies, a suggestion was made that a monoacylated 
cysteine in the pharmacophore of the compound in Figure 3.1 might reduce its agonist activity, 
rendering it more useful as an imaging probe.  
An antagonist ligand with specificity for TLR2 and conjugated to fluorescent dye would be 
a valuable imaging probe for pancreatic adenocarcinoma and could improve the surgical resection 
of pancreatic tumors.  Fitting with the central theme of our research, a peptide-based molecule 
probe was desired. Our synthetic goals for the fluorescent probe were to further simplify the 
binding motif and develop a cysteine-based monomer that could be easily incorporated into 
conventional solid phase peptide synthesis. A strategy employing differentially acid-sensitive 
protecting groups was developed to synthesize a monoacylated monomer with appropriately spaced 
and oriented synthons as elucidated in previous SAR work.   
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3.2 Results and Discussion 
At the outset of this research project, the goal was to synthesize a monoacylated analog of a 
previously reported TLR2 ligand with a customized fluorescent dye to match the filter set of the 
imaging platform used by our collaborators. The peptide portion of molecule appeared amenable 
to conventional solid phase peptide synthesis, while some of the non-canonical monomers would 
have to be synthesized using organic chemistry techniques. Specifically the monoacylated L-cysteine 
and the fluorescent dye each required separate synthesis and characterization prior to peptide 
synthesis.   
 
3.2.1 Fmoc-Cys(POE)-OH Synthesis 
The amino acid monomer required for TL2RL synthesis was Fmoc-Cys(S-
[palmitoyloxyethyl])-OH (Fmoc-Cys(POE)-OH).  A simple retrosynthetic scheme was devised for 
this monomer and is shown in Scheme 3.1.   The first disconnection would have resulted in two 
synthons, a commercially available Fmoc-Cys-OH and a palmitate ester with a terminal leaving 
group. The ester could further be disconnected to two other commercially available products: 
palmitic acid and a 2-halogenated ethanol.  
 The palmitate ester was prepared in one step from either of two reactions. The schemes for 
both reactions are shown in Scheme 3.1.  In reaction (A), palmitoyl chloride was reacted with 2-
iodoethanol in DCM. In reaction (B), palmitic acid was condensed with 2-iodoethanol using 
dicyclohexylcarbodiimide (DCC) and catalytic 4-dimethylaminopyridine (DMAP) in DCM.  Both 
products were purified by recrystallization and resulted in high yields. Reaction (A) was preferred 
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for the synthesis of compound 3.1 because of the dicyclohexylurea was difficult remove from 
reaction (B).  
 From the retrosynthetic analysis, the next step in the forward route was to combine 
compound 3.1 with Nα-Fmoc protected L-Cysteine, which itself was prepared from treating Fmoc-
Cys(Trt)-OH with TFA.  This substitution reaction was attempted by deprotonation of the 
sulfhydryl on the cysteine and mixing with the palmitate ester, 3.1. Unfortunately, very little of the 
correct sulfur alkylated product was observed by reaction monitoring with TLC and HPLC-MS.  
The majority product observed (Figure 3.2) was the result of substitution with the dibenzofulvene 
product of Fmoc deprotection. Many organic and inorganic bases were screened to find one that 
would balance the deprotonation of the sulfhydryl without removing the Fmoc protecting group. 
Unfortunately none were found that could produce reasonable yields of the desired product.   
H
N
S
O O
O
OH
O
O HN
SH
O
OH
O
O
Fmoc-L-Cys-OH
O (CH2)14CH3
O
LG
LG = Cl, Br, I
LG
OH
HO (CH2)14CH3
O
 
Scheme 3.1. Retrosynthetic analysis of Fmoc-Cys(POE)-OH. 
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Scheme 3.2. Synthesis of 2-iodoethyl palmatate 3.1. 
Since the first approach to preparing Fmoc-Cys(POE)-OH failed due to the incompatibility 
of the base labile Fmoc PG, an alternative scheme (Scheme 3.3) was devised with orthogonal PGs.  
This scheme began with S-trityl protected L-cysteine and subsequently modified both the amino 
and carboxylic acid functional groups with PGs sensitive to hydrogenolysis.  Next the S-trityl group 
was removed by treatment with TFA and compound 3.1 was substituted.  Unfortunately the final 
step of removing the carboxybenzyl (Cbz) and benzyl (Bn) PGs failed.  This failure was likely due to 
sulfur poisoning of the palladium catalyst.  A Raney nickel catalyzed reduction was also attempted 
but resulted in compound desulfurization.    
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Figure 3.2. Structure of major product from the first attempt to synthesize Fmoc-Cys(POE)-OH.  
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Scheme 3.3. Synthetic route for the preparation of Fmoc-Cys(POE)-OH via hydrogenolysis 
sensitive PGs.  
  
The next synthetic scheme made use of protecting groups that were differentially sensitive 
to acid. Scheme 3.4 depicts the route starting from Boc-Cys(Trt)-OH.  First the carboxylic acid was 
esterified with t-butanol.  Next the most acid-sensitive PG, S-trityl, was removed by treatment with 
1% TFA in DCM at 0 °C. Next the substitution reaction was performed by stirring palmitate ester 
3.1 with compound 3.3 and DIEA in peptide grade DMF at elevated temperature.  The N-Boc 
group was removed by treatment with 10% TFA in DCM at 0 °C, and an N-Fmoc group was 
installed.  Finally the OtBu ester was hydrolyzed in neat TFA to produce the final desired Fmoc-
Cys(POE)-OH, 3.6. 
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Scheme 3.4. Synthetic route for Fmoc-Cys(S-[palmitoyloxyethyl])-OH, 3.6. 
 
 
3.2.2 IR-780-COOH Synthesis 
 Many commercially available fluorescent dyes are tremendously expensive. For instance LI-
COR sells a fluorescent dye (IRDye® 800CW) similar to one used in this project for $1,990/50 
mg. The precursor for our dye (IR780) was purchased from Sigma for $74/1 g.  To incorporate the 
dye into solid phase peptide synthesis (SPPS), a carboxylic acid was required. This functional group 
was attached to the acquired dye through Suzuki coupling with 4-carboxyphenyl boronic acid 
(Scheme 3.5).  After silica gel chromatography, the purified dye was isolated in 56% yield.    
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Scheme 3.5. Synthetic route for conjugated IR780 dye. 
 
3.2.3 TLR2L Peptide Synthesis 
 Peptide synthesis was according to Scheme 3.6.  TentaGel Rink amide resin (0.15 g, 0.036 
mmol) was used as solid support and all amino acids were coupled using conventional Nα-
Fmoc/tBu SPPS strategy and HCTU/NMM activation.  An Fmoc-protected oligomeric PEG linker 
acid called PEGO was incorporated before and after the short pharmacophore (DSer-Gly-
Cys(POE)) to help solubilize the final lipopeptide. After the completion of synthesis, the product 
was cleaved from resin using TFA cocktail.  Instead of typical ether precipitation, the blue-green 
acid filtrate was reduced in vacuo and reconstituted in MeOH prior to HPLC purification.  After 
purification and lyophilization, 33.4 mg (0.01753 mmol, 49%) of blue-green product was isolated.   
71 
 
.
1) a) Remove Fmoc, b) Couple 4 eq Fmoc-PEGO-OH, 4 eq HCTU, 15 eq NMM 
2) a) Remove Fmoc, b) Couple 4 eq Fmoc-D-Ser(Trt)-OH, , 4 eq HCTU, 15 eq NMM 
3) a) Remove Fmoc, b) Couple 4 eq Fmoc-Gly-OH, 4 eq HCTU, 15 eq NMM 
4) a) Remove Fmoc, b) Couple 4 eq Fmoc-Cys(POE)-OH, 4 eq HCTU
5) a) Remove Fmoc, b) Couple 4 eq Fmoc-PEGO-OH, 4 eq HCTU, 15 eq NMM
6) a) Remove Fmoc, b) Couple 4 eq IR780-COOH, 4 eq HCTU, 15 eq NMM
7) TFA Cleavage
8) Lyophilization
9) RP-HPLC purification
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Scheme 3.6.  SPPS strategy used for TL2RL-780.   
 
3.2.4 TLR2L Characterization 
3.2.4.1 Product Purity and Identification. Figure 3.3 depicts the HPLC chromatogram of 
purified TLR2L-780 peptide.  The purity of the compound was measured as a percentage of the 
total area under the curve of the HPLC trace. Purity was recorded as 96.4% with a retention time 
of 25.2 min.  The peptide was also analyzed by MALDI-TOF; M+ was recorded as 1790.0989 (exp. 
1790.0716). 
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Figure 3.3. HPLC chromatogram of purified TLR2L-780. UV absorbance was monitored at 222 
nm (red) and 300 nm (blue).  
 
 
Figure 3.4. Optical characterization of IR780-COOH (3.7) and TLR2Li-780.  Boxes A and C 
show absorbance and fluorescence emission spectra for IR780-COOH, 3.7, respectively. Boxes B 
and D show absorbance and fluorescence emission spectra for TLR2LI-780. Experiment and 
figure done with Dr. Allison Cohen (Morse Lab).  
-20
0
20
40
60
80
100
0 10 20 30 40
Ab
so
rb
an
ce
 (m
AU
) 
Time (min) 
73 
 
3.2.4.2 Optical Characterization. Both the IR780-COOH dye (3.7) and TLR2L-780 
peptide were subjected to optical testing measuring both absorbance and fluorescence emission.  
Figure 3.4 shows the spectra recorded from these experiments. The Stokes shift of the peptide 
increased from the 32 nm of compound 3.7 to 40 nm.  This shift is beneficial for imaging as a 
larger Stoke reduces the signal to noise due to the smaller overlap in emissions and absorption. 
This characteristic also has the effect of lessening photo quenching of the dye.   
 
3.2.4.3 Lipophilicity Measurement. The lipophilicity of TLR2L-780 was determined by 
miniaturized shake flask method using an HPLC-triple quadruple-mass spectrometry for 
determining ligand concentrations, as was done in Chapter 2. The phosphate buffered solution 
was buffered to physiologic pH and the LogD7.4 was measured as 2.05 ± 0.17. This measurement of 
ligand lipophilicity is indicative of a compound with low aqueous solubility.  
 
3.2.5 Biological Testing 
 The final fluorescent dye-conjugated peptidomimetic was tested by our collaborators in Dr. 
David Morse’s group at the Moffitt Cancer Center.  Amanda S. Huynh was the lead scientist for 
these experiments.  First the compound was tested for in cyto binding affinity on a pancreatic 
tumor cell line with endogenous TLR2 surface expression (19,300 per cell).  The binding affinity 
was measured using a time-resolved fluorescence (TRF) competition assay.18 Figure 3.5 shows the 
binding curve, Ki= 16 ± 1.4 nM, R
2= 0.85, n=3.   
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Figure 3.5. Competition binding assay SU.86.86 pancreatic tumor cells with endogenous TLR2 
expression (n=3, R2=0.90). Experiment and figure done by Amanda S. Huynh.   
 
 
Figure 3.6. Functional bioassay measuring downstream signaling of TLR2 upon treatment with 
listed compound. Experiment and figure done by Amanda S. Huynh. 
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 Next the Moffitt team tested the TLR2L-780 peptide in a bioactivity functional assay. The 
compound was shown to inhibit receptor activity compared to the control agonists (Pam2CSK4, 
Pam3CSK4, HKLM) shown in Figure 3.6.  The group’s previously reported diacyl-TLR2L-800 
compound (Figure 3.1)7 was also tested in this experiment and demonstrated comparable activity 
to the controls. The IC50 of the new compound was measured at 361 nM. Further in vitro 
experiments were carried out to determine TLR2L-780 selectivity for the TLR2.  No agonistic 
activity was observed in human TLR3, TLR4, TLR5, TLR7, TLR8 or TLR9. Additionally, no 
inhibition of stimulation was measured for on the human TLR3, TLR5, TLR7, TLR8 or TLR9 
receptors.  
  
 
Figure. 3.7. In vivo and ex vivo near infrared (NIRF) guided imaging using TLR2L-780.  A) 
Snapshot of real-time intraoperative fluorescence guided imagery of orthotopic pancreatic tumor. 
B) Ex vivo NIRF image of excised tumor. C) Pre-operative and post-operative (D) tomographic 
images of NIRF guided surgery.  Experiment performed by Amanda S. Huynh. 
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Finally the Moffitt Team tested the TLR2L-780 peptide for in vivo tumor binding and in 
an intraoperative fluorescence guided surgery. Figure 3.7 highlights these experiments. The 
fluorescently labeled peptide ligand is shown to bind an orthotopic SU.86.86 pancreatic tumor 
(Figure 3.7, A). During a real-time image guided surgery the injected fluorescent peptide probe 
enabled the surgeon to remove the tumor cleanly at its margins. Figure 3.7, box C shows 
tomographic imagery of the tumor in place pre-surgery and box D shows complete resection of the 
tumor post-surgery. 
 
3.3 Conclusions 
A new toll-like receptor 2 binding peptide was designed and synthesized based upon 
structural modification of a previously reported agonist peptides.  A synthetic scheme was 
developed to produce the cysteine-based monomer used in the ligand’s pharmacophore. 
Additionally, a fluorescent tag with was designed and synthesized. Conventional peptide synthesis 
was used to prepare the final peptide-dye conjugate in good yields.   
The new fluorescently labeled peptide targeting ligand was tested for biological function by 
our collaborators in the Moffitt Cancer Center.  It was determined to be a highly selective ligand 
for human TLR2 with higher binding affinity than the diacyl version previously reported. The 
result of exchanging the diacyl-cysteine monomer with the new cysteine-palmitate ester and the IR-
780 dye completely abrogated the biological effect seen in all previously reported TLR2 lipopeptide 
ligands. The novel antagonist, TLR2L-780, is the most potent TLR2 inhibitor reported to date and 
the only TLR2 antagonist-based fluorescence imaging probe. Finally the new imaging probe was 
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used in an intraoperative guided surgery and the orthotopic tumor was cleanly resected with 
guidance from the new probe. 
 
3.4 Experimental  
3.4.1 Materials and Instrumentation 
Nα-Fmoc protected amino acids, and peptide synthesis reagents were purchased from 
ChemImpex (Wood Dale, IL).  Rink amide TentaGel S resin (0.2 mmol/g) was acquired from 
Rapp Polymere (Tubingen, Germany). The D-serine amino acid was purchased with t-butyl and Nα-
Fmoc protecting groups. An Fmoc-protected version of PEGO (20 atom linker: 19-amino-5-oxo-
3,10,13,16-tetraoxo-6-azanonadecan-1-oic acid residue) was purchased from Novabiochem.  
IRDye780 and 4-carboxyphenylboronic acid was purchased from Sigma Aldrich (St. Louis, MO). 
Peptide synthesis solvents, dry solvents, and solvents for HPLC (reagent grade) were acquired from 
VWR (West Chester, PA), Sigma-Aldrich (Milwaukee, WI), or ChemImpex (Wood Dale, IL) and 
were used without further purification unless otherwise noted.   
A Varian solvent delivery module with Dionex UVD340U diode array detector was used 
for preparative HPLC chromatography.  Analytical scale HPLC was performed using a Dionex 
P680 system with quaternary pumps, autosampler, and diode array detector.  Mass spectral analysis 
was performed with either Agilent 6540 QTOF with dual Jet-Stream ESI source, Agilent 6460 
QQQ  with Jet-Stream ESI source coupled to Agilent 1260 Infinity HPLC, Agilent LC/MSD VL 
single quadrupole with Agilent 1100 series HPLC, or Applied Biosystem 4700 MALDI-TOF-TOF 
proteomics analyzer with 355nm Nd:YAG laser. Peptide was assembled using a ChemGlass 
manual peptide vessel and lyophilized on a Labconco Freeze Dry/Shell Freeze System.  Absorbance 
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and Fluorescence measurements were taken on a Tecan Infinite M-1000 PRO multimode 
microplate reader.  
Nuclear Magnetic Resonance (NMR) experiments were carried out on either a 400 MHz 
Varian INOVA instrument with 5 mm ASW probe, a 500 MHz direct drive Agilent instrument 
with TR cryoprobe, or a 600 MHz Varian INOVA instrument with 5 mm BB rt probe.  Spectra 
were analyzed by ACD labs NMR Workbook 2015. Chemical shifts (δ) were reported in parts per 
million (ppm) and corrected to residual solvent signals.   
 
3.4.2 Experimental Procedures 
3.4.2.1 Monomer Synthesis 
 
O
O
(CH2)13CH3I
 
2-iodoethyl palmitate, 3.1 
Palmitoyl chloride (3.33 mL, 10.9 mmol) and 2-iodoethanol (1.02 mL, 13.1 mmol) were 
combined in 300 mL dichloromethane.  Triethylamine (3 mL, 22 mmol) was slowly added with 
mechanical stirring at room temperature.  The reaction was concentrated after 1 hour. An off-
white pure compound was isolated by recrystallization from DCM/MeOH (4.33 g, 10.9 mmol, 
97%); 1H NMR (400 MHz, CDCl3) δ 4.33 (t, J=6.81 Hz, 2H), 3.30 (t, J=6.78 Hz, 2H), 2.34 (t, 
J=7.52 Hz, 2H), 1.58-1.70 (m, 2H), 1.21-1.34 (m, 24H), 0.89 (t, J=6.76 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 173.2, 64.3, 34.2, 31.9, 29.7, 29.6, 29.4, 29.3, 29.2, 29.1, 24.9, 22.7, 14.1, 0.5; 
GC-MS m/z [M+] calcd for  C18H35IO2 410.168, found 410.040. 
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BocHN
S
O
OtBu
Trt  
tert-butyl N-(tert-butoxycarbonyl)-S-trityl-L-cysteinate, 3.2 
Boc-L-Cys(Trt)-OH (2.2 g, 4.78 mmol) was dissolved in 300 mL dichloromethane.  N,N- 
dicyclohexylcarbodiimide (1.2 g, 5.7 mmol), tert-butanol (0.69 mL, 7.17 mmol), and 4-
dimethylaminopyridine (0.0354 g, 0.23 mmol) were combined with the cysteine with mechanical 
stirring.  The reaction was refluxed for 15 hours and the dicyclohexylurea by-product was filtered 
upon cooling (0 °C).  The filtrate was washed with sat. aq. NaHCO3 and brine. The organic layer 
was dried over anhydrous MgSO4, the solvent was removed under vacuum. Crude residue was 
purified by silica gel chromatography (20% EtOAc/hexanes) to give 3.2 as a solid white powder 
after concentration (2.28 mg, 4.63 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 7.40 (br d, J=7.86 
Hz, 5H), 7.12-7.34 (m, 13H), 5.08 (br d, J=7.26 Hz, 1H), 4.13-4.26 (m, 1H), 2.52 (br s, 2H), 1.41-
1.46 (m, 15H); 13C NMR (101 MHz, CDCl3) δ 169.7, 155.0, 144.4, 129.6, 128.3, 128.0, 127.7, 
127.7, 129.5, 127.9, 126.7, 82.2, 79.7, 66.4, 52.9, 34.5, 28.3, 27.9 HRMS (ESI-QTOF) m/z [M + 
Na]+ calcd for  C31H37NO4S 542.2336, found 542.2347, 2.03ppm. 
 
BocHN
SH
O
OtBu
 
tert-butyl (tert-butoxycarbonyl)-L-cysteinate, 3.3 
Compound 3.2 (1.3 g, 2.5 mmol) was dissolved in 1% TFA in DCM with triethylsilane 
(0.6 mL, 3.75 mmol). The deprotection was stirred at 0 °C, monitored by TLC with Ellman’s 
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reagent as a developing agent. After 5 hours, the solvent was removed under vacuum yielding an 
oily residue. Crude residue was purified by silica gel chromatography (50% EtOAc/hexanes) to 
give 3.3 as a thick oil (0.544 g, 1.96 mmol, 78%). 1H NMR (400 MHz, CDCl3)  5.41 (br s, 1H), 
4.47 (br s, 1H), 2.96 (br dd, J=3.80, 8.62 Hz, 1H), 1.48 (br s, 20H); 13C NMR (101 MHz, 
CHLOROFORM-d) δ 169.6, 155.0, 82.7, 79.9, 53.8, 42.0, 29.7, 27.9, 28.3, 18.1; HRMS (ESI-
QTOF) m/z [M + Na]+ calcd for  C12H23NO4S 300.1240, found  300.1246, 2.00ppm. 
 
BocHN
S
O
OtBu
O O
(CH2)13CH3  
(R)-2-((3-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl palmitate, 3.4 
Compound 3.3 (126.6 mg, 0.4564 mmol) was dissolved in peptide grade DMF with 
compound 4 (229.2 mg, 0.5592 mmol). Diisopropylethylamine (0.159 mL, 0.9128 mmol) was 
added to the reaction with stirring and the reaction was heated to 80 °C. The reaction was 
monitored by TLC and iodine chamber for 15 h and then solvent was removed under vacuum. 
Crude residue was purified by silica gel chromatography (25% EtOAc/hexanes) to give 3.4 as a 
colorless oil (243 mg, 0.434 mmol, 95%). 1H NMR (500 MHz, CDCl3) δ 5.34 (br d, J=6.97 Hz, 
1H), 4.41 (br d, J=6.83 Hz, 1H), 4.28-4.35 (m, 1H), 4.21 (dt, J=1.97, 6.73 Hz, 1H), 3.64-3.71 (m, 
1H), 2.91-3.07 (m, 1H), 2.78 (t, J=6.72 Hz, 1H), 2.27-2.40 (m, 2H), 1.56 (br s, 9H), 1.48 (s, 7H), 
1.45 (s, 7H), 1.25 (s, 22H), 0.88 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 173.5, 169.8, 155.1, 82.6, 
79.9, 77.3, 63.7, 63.1, 53.9, 41.6, 34.9, 34.2, 34.1, 31.9, 31.3, 29.6, 29.6, 29.6, 29.3, 28.3, 27.9, 
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24.9, 22.6, 14.1; HRMS (ESI-QTOF) m/z [M + H]+ calcd for  C30H57NO6S 560.3979 ([M+Na]
+ 
582.3799), found  560.3997, 3.21 ppm (582.3818, 3.26 ppm). 
 
 
FmocHN
S
O
OtBu
O O
(CH2)13CH3  
(R)-2-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-3-oxopropyl)thio)ethyl 
palmitate, 3.5 
Compound 3.4 (243 mg, 0.434 mmol) was dissolved with 10% TFA in DCM at 0 °C. The 
deprotection was monitored by TLC with ninhydrin reagent developing. After 4 hours, the solvent 
was removed under vacuum and diisopropyethylamine (0.151 mL, 0.868mmol) was added with 
Fmoc-OSu (176 mg, 0.521 mmol) in anhydrous DCM. After 2 hours the reaction was 
concentrated until reduced pressure and the crude residue was purified by silica gel 
chromatography (30% EtOAc/hexanes) to give 3.5 as an off-white semisolid (0.2072 mg, 0.3038 
mmol, 70%). 1H NMR (500 MHz, CDCl3) δ 7.78 (br d, J=7.52 Hz, 2H), 7.62 (br d, J=7.40 Hz, 
1H), 7.41 (br t, J=7.46 Hz, 2H), 7.29-7.37 (m, 2H), 6.05-6.13 (m, 1H), 6.09 (s, 1H), 5.66 (br d, 
J=7.46 Hz, 1H), 4.52 (br d, J=5.32 Hz, 1H), 4.31-4.47 (m, 1H), 4.31-4.47 (m, 1H), 4.09-4.30 (m, 
2H), 3.70 (d, J=5.75 Hz, 1H), 3.05 (br dd, J=4.62, 17.03 Hz, 1H), 2.79 (br t, J=6.48 Hz, 1H), 2.33-
2.41 (m, 1H), 2.36 (t, J=7.55 Hz, 1H), 2.30 (br t, J=7.58 Hz, 1H), 1.57 (br s, 5H), 1.51 (s, 7H), 
1.20-1.38 (m, 23H), 0.89 (br t, J=6.91 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.5, 173.3, 
143.7, 143.7, 141.3, 127.7, 127.0, 125.1, 119.9, 83.0, 67.4, 67.1, 63.0, 56.7, 54.3, 53.7, 47.1, 
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34.9, 34.1, 34.0, 32.4, 31.9, 31.4, 30.4, 29.6, 29.6, 29.6, 29.4, 29.3, 29.2, 29.1, 28.0, 27.9, 25.8, 
25.4, 25.3, 25.0, 24.9, 24.7, 24.6, 22.6, 18.6, 17.4, 14.1, 12.0; HRMS (ESI-QTOF) m/z [M + H]+ 
calcd for  C40H59NO6S 682.4136 ([M+Na]
+ 704.3955), found 682.4156 2.93 ppm (704.3978 3.27 
ppm). 
 
 
FmocHN
S
O
OH
O O
(CH2)13CH3  
N-(((9H-fluoren-9-yl)methoxy)carbonyl)-S-(2-(palmitoyloxy)ethyl)-L-cysteine, 3.6 
Compound 3.5 (74.2 mg, 0.109 mmol) was dissolved in 50% TFA in DCM.  Solvent was 
removed under reduced pressure after 2 h.  Final product was allowed to dry overnight under high-
vacuum, yielding off-white semisolid compound 3.6. 1H NMR (500 MHz, CDCl3) δ 7.77 (br d, 
J=7.14 Hz, 2H), 7.61 (br s, 2H), 7.41 (br t, J=6.86 Hz, 2H), 7.29-7.37 (m, 2H), 5.73 (br s, 1H), 4.66 
(br s, 1H), 4.43 (br s, 1H), 4.34 (br t, J=5.63 Hz, 1H), 4.24 (br d, J=6.86 Hz, 2H), 3.65-3.73 (m, 
2H), 2.95-3.23 (m, 1H), 2.79 (br s, 1H), 2.20-2.42 (m, 2H), 1.53-1.72 (m, 2H), 1.26 (br s, 26H), 
0.89 (br t, J=6.45 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.3, 174.1, 156.0, 143.6, 143.6, 
141.3, 127.8, 127.1, 125.1, 120.0, 67.5, 63.1, 53.5, 47.0, 34.3, 34.2, 31.9, 31.2, 29.7, 29.6, 29.6, 
29.5, 29.4, 29.2, 29.1, 24.9, 22.7, 14.1; HRMS (ESI-QTOF) m/z [M + H]+ calcd for  C36H51NO6S 
626.3510 ([M+Na]+ 648.3329) found 626.3538, 4.47 ppm (648.3345, 2.47 ppm). 
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N N
+
COOH
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IR780-COOH, 3.7 
Commercially available IR780 dye (330 mg, 0.5 mmol) was refluxed in MeOH/H2O (v/v) 
with 4-carboxyphenyl boronic acid (150 mg, 0.9 mmol) and Pd(PPh3)4 (5 mol%).  The reaction was 
allowed to progress overnight and then dried in vacuo which produces solid, blue-green flakes.  The 
crude product was purified with silica gel chromatography (50% MeOH/DCM) to yield 
compound 3.7 as blue-green crystalline solid (210 mg, 0.279 mmol, 56%). 1H NMR (400 MHz, 
DMSO-d6) δ 8.07 (d, J=8.12 Hz, 2H), 7.45 (d, J=7.45 Hz, 2H), 7.31 (d, J=3.86 Hz, 4H), 7.02-7.21 
(m, 6H), 6.18 (d, J=14.13 Hz, 2H), 4.06 (br t, J=7.13 Hz, 4H), 2.65 (br t, J=6.29 Hz, 4H), 1.92 (br s, 
2H), 1.58-1.80 (m, 4H), 1.10 (s, 12H), 0.90 (s, 6H); 13C NMR (151 MHz, CDCl3) δ 172.1, 148.6, 
142.1, 140.9, 131.1, 130.4, 128.4, 124.9, 122.3, 110.2, 99.4, 48.8, 45.7, 27.7, 24.7, 21.2, 20.7, 
11.6; HRMS (ESI-QTOF) m/z [M]+ calcd 625.3789 for  C43H49N2O2, found  625.3811, 3.52 ppm. 
 
3.4.2.2 Ligand Synthesis, Purification, and Characterization. TLR2L-780 was synthesized 
by SPPS strategy following the outline given in Scheme 3.6. Resin was initially swollen in DCM for 
20 min (2x), washed with NMP (2x), and then the Fmoc-protecting group removed with 20% 
piperidine, 2% DBU in DMF (2 x 20 min).  Next the resin was washed with NMP (3x), DCM (3x), 
and finally with NMP (3x). The subsequent residue was coupled using 4 eq. of Fmoc-protected 
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amino acid, 4 eq. of HCTU and 15 eq. of NMM in NMP.  Kaiser Assay was used to qualitatively 
test for reaction completion. The washing, Fmoc-deprotection, and coupling steps were repeated as 
indicated in Scheme 3.6 for each subsequent monomer. 
Infrared dye 780 was reacted through Suzuki coupling with 4-carboxyphenylboronic acid as 
shown in Scheme 3.6 to produce the IR780-COOH monomer.  The dye conjugate was then coupled 
to the N-terminus of TLR2Li on-resin intermediate with HCTU activation (3 eq. IR780-COOH, 3 
eq. HCTU and 6 eq. DIEA in DMF).  Crude peptide was cleaved from the resin with a cocktail (10 
mL) of TFA, water, and TIS (95:2.5:2.5, v/v). Resin agitation was accomplished by N2 gas bubbling 
over 4 h at room temperature. The filtrate was concentrated in vacuo.  The residue from cleavage 
was dissolved in 50/50 MeOH, H2O (v/v) and purified with the MeOH HPLC method described 
below. Blue-green solid product was isolated as crude TLR2L-780 compound.  
Purity of the peptide was ensured using analytical HPLC. The peptide was 
chromatographed on an AAPPTec Spirit Protein C-8 column , 250 x 46 mm, 5 µm with a linear 
gradient of 25-100 % B over 50 min, where  A was H2O + 0.1% TFA and B was MeOH + 0.1% 
TFA.  Pure peptide was dissolved (1 mg/mL) in DMSO, stored at −20°C, and protected from light. 
Working solutions of 10 µg/mL were prepared from dilutions of the DMSO stocks in deionized 
water.  
 
3.4.2.3 Mass Spectral Analysis: QToF and MALDI-TOF. MALDI -TOF experiments were 
used to analyze both crude and pure peptides. Samples were premixed 1:1 (v/v) with a saturated 
solution of α-cyano-4-hydroxycinnamic acid and then 500 nL was spotted on the MALDI plate. 
The instrument was run in positive, reflective mode.  
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For QToF characterization of purified peptides, the samples were introduced to the mass 
spectrometer as a direct infusion from the HPLC.  The instrument was set to high resolution 
mode in extended dynamic range.  Only positive polarity was measured. Real-time reference 
masses were infused in the second nebulizer during the acquisition.   
 
3.4.2.4 Lipophilicity Measurement. First, the triple quadrupole mass spectrometer was set 
up as described in Chapter 2. The deviation from the procedure outlined in Chapter two is that 
an Alltech Alltima Cyano 100Å 5 µm (4.6 mm x 250 mm) HPLC column was used to 
chromatograph the peptide ligand into the spectrometer.  Transitions of double charged pre-cursor 
ion (the most abundant) were mapped and optimized for the TLR2L. A standard curve was setup 
to measure unknown peptide concentrations.  A 2.5 µM solution of ligand in sodium phosphate 
(25 mM, pH 7.4) was vortexed with three ratios of n-octanol and centrifuged to better partition the 
separated layers. Triplicate measurements of ligand concentration in each layer were used to 
calculate the LogD7.4. 
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CHAPTER FOUR: 
DEVELOPMENT OF NOVEL TARGETED IMMUNOCONJUGATES FOR USE AS 
PEPTIDE-TARGETED IMMUNE EFFECTORS 
 
4.1 Introduction 
The adaptive immune system is an immensely complex system of checks and balances that 
simultaneously protects against pathogens as well as aberrant cells while maintaining self-tolerance. 
Briefly, T cells are able to molecularly recognize and identify abnormal cells or pathogens via 
antigens expressed on the cell surface (Figure 4.1). In response to this recognition, T helper (Th) 
cells release an array of cytokines to attract other immune modulators such as natural killer cells 
and B cells to the affected area. Additionally, Th cells will attract and activate cytotoxic T cells, all 
of which, in concert with other immune modulators, will destroy the targeted cell. Inherent in this 
process are many molecular recognition events, or immune checkpoints, that can either enhance 
or dampen the immune response. Cancer cells use many different immune suppression strategies 
including the expression of proteins that prompt the downregulation of the immunologic 
response.1 Disrupting this evasion by using so-called immune checkpoint inhibitors to blockade 
the signals has been a revolutionary idea in cancer treatment, and is currently a promising research 
target.2-5  
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Ipilimumab was the first and still only FDA approved anti-cytotoxic T-lymphocyte antigen-4 
(αCTLA4) immune effector.  It was the first approved checkpoint inhibitor for treatment of 
metastatic melanomas in 2011.6 This drug was the first non-standard chemotherapeutic to 
substantially increase survival outcomes for advanced, surgically unresectable melanomas.7 A few 
years later, two new immune effectors targeting the programed cell death protein-1 (αPD-1) were 
approved for metastatic melanomas in 2014.8 Nivolumab and pembrolizumab are both αPD-1 
antibodies used for analogous blockade therapy, and both received new indications for metastatic 
squamous non-small cell lung cancer (NSCLC) in 2015. In fact, lung cancer indications are more 
frequently being assigned to these immunotherapeutics.9-11  Many additional new immune effectors 
are currently being researched and several have made their way to various stages of preclinical and 
clinical trials.12 
 
 
Figure 4.1. Key cell surface molecular interactions in T cell signaling. 
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The downside to these new armaments of antibody drugs comes from an over-activation of 
the systemic immune system; almost all toxicity seen from these new drugs is termed immune 
related adverse effects (irAE). Typical issues include dermatitis 40%,13 diarrhea/colitis 30%,14 and 
sometimes hepatitis.15  Clinical evidence suggests that the irAE from the αPD1 class of antibodies 
is not as bad as that from the αCTLA4, however typical combinations and sequential protocols 
make use of both.16,17  Once irAEs are observed in the clinical setting, the immunotherapy is often 
discontinued, until the treatment of the side effects through the administration of steroids, tumor 
necrosis factor-α inhibitors (infliximab), and immunosuppression.15 Not only do these 
interventions cost time and money, the patient loses critical time without the immunotherapy.   
 Because immune checkpoint inhibitors are antibodies with an affinity for proteins on the 
surface of immune cells, they are technically a type of targeted therapy. However these current 
checkpoint inhibitors have little discrimination for tumor cells. The vision of the current study was 
to reduce the immune related adverse events (irAEs) and increase potency by targeting the PD-1 
blockade using established tumor cell surface, targeted ligand (TL) technology to concentrate the 
immune effectors in the tumor microenvironment.   
Although the incidence of lung cancer in the US has declined in recent decades (due to 
fewer smokers), the American Cancer Society still lists lung cancers as the second most frequently 
diagnosed cancers among both men and women.18  Owing to both its severity and the large 
number of affected people, this insidious disease also boasts the highest cancer death rates in the 
US with one and five year survival rates at 44% and 17% respectively.18 Unfortunately, the rest of 
world has an increasing number of smokers and the WHO data reports 1.6 million people died of 
lung cancer worldwide in 2015. Treatment options depend on the subtype and stage of disease but 
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most often include surgery, radiation therapy, and chemotherapy. Patients with advanced stages of 
the largest subtype, non-small cell (83%), can benefit from recent advances in immunotherapy.   
The δ-opioid receptor (DOR) is characterized as a 7-transmembrane GPCR that has normal 
expression in brain tissue, where it understood to be involved with analgesic effects upon agonistic 
binding. In the 1990s this extracellular receptor was found to be overexpressed on the surface of 
NSCLC tumors.19,20 The use of this receptor for imaging and characterization of lung cancer 
tumors demonstrated in subsequent research.21,22 Previous work in our group capitalized on this 
overexpression through the synthesis of a dipeptide antagonist for the delta-opioid receptor and 
coupling fluorescent dyes with the goal of real-time intraoperative guided surgical resections.23,24 
 Combining the group’s previous work with the novel idea of target immunotherapy led to 
the goal of the current research project: to synthesize bifunctional molecules that target tumor cells 
through overexpressed extracellular receptors and subsequently effect a local immune response in 
the tumor micro environment.  Because these biomolecules can target and concentrate at the 
tumor, the resulting immunoconjugate should have a larger therapeutic window than current 
analogous therapies.  The reduction of systemic toxicities would also likely require the use of lower 
levels of systemically circulating drug. Finally this new class of immune modulators could be more 
pharmacoeconomic since doses of costly antibodies might be reduced.   
 
4.2 Results and Discussion 
4.2.1 Targeting Ligand Design and Synthesis 
Often referred to simply as ‘DmtTic,’ the delta opioid receptor (DOR) targeting peptide 
ligand is a logical first choice to test the viability of peptide-targeted checkpoint inhibitors.  The 
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pharmacophore is well characterized as a selective, high affinity ligand for the δ-opioid receptor.25,26 
The synthesis is facile with conventional peptide synthesis techniques, and is amenable to 
bioconjugations with simple modifications.  While the DOR is understood to be a bonafide cell 
surface marker of NSCLC, its expression in normal tissues is mostly limited to the CNS.  DmtTic’s 
peptidic nature limits its permeation of the blood brain barrier, especially once covalently attached 
to a 150 kDa antibody.   
Peptide synthesis was performed using conventional 9-fluorenylmethoxycarbonyl (Fmoc) 
based solid-phase peptide synthesis (SPPS).  TentaGel MB NH2 resin was chosen as an appropriate 
resin due to the swelling characteristics of the polyethylene glycol (PEG) linker in a variety of both 
aqueous and polar organic solvents. For these reasons the resin was found to be efficient for the 
peptide synthesis steps, including a reductive amination step using aqueous formaldehyde. Scheme 
4.1 outlines the synthesis of the DmtTic targeting ligand. As in previous research projects, the C-
terminal lysine of each of the targeting ligand analogs was an important synthetic tool which 
allowed for creating a branched structure. By employing an orthogonal protecting group (Alloc) on 
the ɛ-amino group, the linear portion of the peptide was completed first. Then the structure was 
branched after alloc deprotection to incorporate the PEG oligomer (Scheme 4.1, bottom product).  
To incorporate two branched elements, a second lysine(Alloc) amino acid was coupled to the first’s 
ɛ-amino group.  The right product on Scheme 4.1 shows this branched TL. This scaffold was used 
to incorporate both a fluorescent dye and an oligomeric PEG monomer.   
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Scheme 4.1.  SPPS strategy used to synthesize the DmtTic targeting ligand. The bottom and right 
products depict how products could have no branching or branching from a C-terminal lysine 
residue in order to incorporate extra elements into the targeting ligand via the remaining primary 
of the terminal lysine.  
 
Methods for conjugating peptides and drugs to biomolecules are described in many 
primary texts, including Hermanson’s Bioconjugate Techniques.27  Scheme 4.2 depicts two strategies 
to conjugate the ɛ-amine of ubiquitous lysine side chains. By pre-activating the DmtTic ligand with 
an ester leaving group, like N-hydroxysuccinimide or N-hydroxysulfosuccinimide (Scheme 4.2, (A) 
and (B) respectively), coupling of ligand with antibody could be affected. These coupling strategies 
were a strategic choice for DmtTic due to its lack of nucleophilic side chains.  For instance, amino 
acid side chains containing amines or sulfhydryls could intramolecularly compete with the lysines 
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on the proteins for the activated ester of DmtTic.  The most nucleophilic functional group on the 
DmtTic targeting ligand was the primary amine on the N-terminus.  Salvadoria et al. have 
previously reported SAR indicating that the N-terminal dimethylated analog of DmtTic retained 
comparable binding affinity and selectivity for the DOR.26  To this end, the N-terminus of DmtTic 
was dimethylated to limit any other competing coupling chemistry of the ligand that could lead 
oligomerization of the DmtTic ligand as well antibody coupling. As shown in Scheme 4.1, the 
dimethylation reaction was done on solid support before alloc deprotection. Initial experiments 
involved reductive amination using 1,3,5-trioxane as a source of formaldehyde, and several 
reductants were surveyed.  Optimal reductive amination was accomplished with aqueous 
formaldehyde (37%), fresh NaBH3CN, and catalytic AcOH.  
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Scheme 4.2. Common conjugation chemistries used to functionalize bio molecules. Rows (a) and 
(b) show activated NHS and Sulfo-NHS esters reacting to form native amide bonds with lysine side 
chains from a biomolecule. 
 
Another crucial design element in the TL was the inclusion of a water soluble linker.  The 
appropriate space between the TL and the antibody is critical for the functionality of both 
components.  A relationship is known to exist between linker length, flexibility and increased 
94 
 
avidity for the target receptor.28,29  Linker length and composition, and also receptor number and 
spacing/relative distance, are critical factors to balance when designing linkers. The linker chosen 
for this DmtTic ligand was an oligomeric polyethylene glycol monomer, or discrete PEG (dPEG), 
that can be purchased in various lengths. Additionally, the polyethylene glycol monomers of the 
linker were intended to enhance aqueous solubility of the relatively hydrophobic DmtTic 
pharmacophore.   
 
N N
O
O N
O
O
Cl-
 
Figure 4.2. Structure of Cyanine Dye 5.5, NHS-ester. 
 
One final contribution to the design of the targeting ligand was the inclusion of a 
fluorescent dye.  For purposes of monitoring biodistribution and pharmacokinetics, a 
commercially available indocyanine green (ICG) derivative dye, named Cy5.5 was purchased. 
Figure 4.2 illustrates the structure of the dye as it was purchased from Lumiprobe. The dye was 
chosen both for its emission and excitation characteristics (678/694 nm respectively) and for its 
NHS-ester. For economic reasons, the dye was not coupled to the peptide while on solid support. 
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Instead the NHS-ester dye was coupled in solution with the purified peptide as shown in Figure 
4.3. 
 
Figure 4.3. Solution-phase modifications to targeting peptide ligand. (a) Cy5.5-NHS ester (1 
equiv.), NEt3 (5 equiv.), MeCN  (b) N-hydroxysuccinimide (3 equiv.) DCC (3 equiv.), MeCN. The 
inset HLPC traces (right of reaction scheme) demonstrate how the reaction was monitored for 
completion of each step. 
 
 In summary, different versions of DmtTic TL were synthesized. The structures of these 
compounds are shown at the end of this chapter and pertinent information is summarized in 
Table 4.1.  Variations included length of dPEG linker, the inclusion of cyanine dye, and type of 
NHS leaving group.  One final compound (4.5) was made with a scrambled pharmacophore by 
reversing the order of amino acids in the pharmacophore. The purpose of this compound was to 
prepare negative-binding control immunoconjugates. After each targeting ligand was synthesized, 
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pre-activated, and lyophilized, they were each fully characterized by HPLC and MALDI-TOF. Prior 
to use, each compound was reconstituted in DMSO to 5 mM.  These targeting ligand stock 
solutions were then used for immunoconjugate synthesis. Unused DMSO solutions were frozen to 
-20 °C and were assayed by HPLC for hydrolysis before use in later immunoconjugate reactions.   
 
Table 4.1 Summary of peptide targeting ligands prepared for subsequent immunoconjugation. 
 Targeting Ligand Linker Dye Activated LG 
4.1 N,N-DiMethyl-Dmt-Tic-Lys-CONH2 dPEG5 -- NHS 
4.2 N,N-DiMethyl-Dmt-Tic-Lys-CONH2 dPEG5 Cy5.5 NHS 
4.3 N,N-DiMethyl-Dmt-Tic-Lys-CONH2 dPEG5 Cy5.5 SulfoNHS 
4.4 N,N-DiMethyl-Dmt-Tic-Lys-CONH2 dPEG13 Cy5.5 NHS 
4.5 N,N-DiMethyl-Lys-Tic-Dmt-CONH2 dPEG5 Cy5.5 NHS 
 
 
4.2.2 Immunoconjugate Synthesis 
 The bioconjugation reaction of activated targeting ligand with antibody is shown in Figure 
4.4.   This cartoon represents the stochastic reaction where the roughly 60 surface accessible lysine 
side chains may react with the activated targeting ligand (presented as blue spheres).  A 
characteristic of this reaction was the random assortment of potential products.  Due to differences 
in concentration, pH, temperature, salt concentration, etc., this reaction produced slightly 
different combinations of products with each batch.  
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Figure 4.4. Bioconjugation reaction for the addition of targeting ligand to immune effector 
antibody. This cartoon is only a representation of possible products of lysine side chains (-NH2) 
and targeting ligand (blue spheres).  
 
Similar batch-wise differences were seen in first-generation antibody-drug conjugates, or 
ADCs.  These targeted therapeutics attach a cytotoxic drug payload to a targeting antibody. 
Typically the drug is linked to the antibody through a cleavable linker which releases the cytotoxic 
payload once the antibody is internalized to its cellular target. While developments in this field 
have elucidated methods to specifically attach payloads to antibodies, the earliest conjugates were 
either lysine or cysteine linked conjugates. An important trait of ADCs is the so-called drug-to-
antibody ratio, or DAR. As the name implies, this value is a measure of the number of drug 
molecules given as a ratio to the number of antibodies. Even with tight production controls this 
value could change slightly for each batch of immunoconjugates.30 
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Because our targeted immunoconjugate scheme reverses the paradigm of ADCs by 
targeting the antibody with its payload, we thought it would be appropriate to rename the payload-
to-antibody ratio. Hence the name, targeted ligand-to-antibody ratio, or TAR.  Analogously to the 
first generation ADCs, our TAR changes slightly between batches but can generally be controlled 
through the conditions set during each conjugation reaction. It serves as one measurable output to 
be used in tracking the efficiency of the conjugation reaction.  
A series of initial experiments were performed to optimize the bioconjugation reaction.  
Table 4.2 lists the tested conditions.  First the pH of the conjugation buffer was varied. A trend of 
increasing TAR followed from increasing the pH of solution to 8.5 in 50 mM HEPES buffer.  
Changing the buffer component from HEPES to phosphate also served to increase the TAR of the 
resulting conjugate. Finally the effects of salt concentration and organic modifier were tested. 
Increased salt concentration had large deleterious effects to the TAR, reducing from 3.63 to 1.46.   
 
Table 4.2. Targeting Ligand to Antibody Ratio (TAR) observed from various buffers during 
immunoconjugation. 
 
 
 
The addition of an organic modifier to the reaction buffer was tested due to poor aqueous 
solubility of the TL. Without organic modifier in the conjugation reaction, DmtTic didn’t mix 
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well in the aqueous solution.  The addition of up to 10% ethanol was qualitatively observed to 
increase solubility. However the resulting TAR was actually lower with the ethanol.  Due the 
compatibility with antibodies and typical use as a cryoprotectant, later tests using ethylene glycol as 
organic modifier yielded high TAR values.   
Table 4.3 shows another measure of reaction efficiency under the given optimization 
conditions: protein recovery.  Due to the measurement error when determining final volumes, one 
of the values was recorded over 100%. However the clear trend suggests that the 10% ethanol 
solution promotes protein recovery. The use of organic modifier was therefore continued in 
further experiments.  
A final variable tested during the optimization experiments was the leaving group (LG).  
Up to this point the DmtTic targeting ligand was preactivated as the N-hydroxysuccinimide ester.  
Due to the previously mentioned solubility issues, a similar leaving group with a single appended 
sulfonate group was synthesized. This N-hydroxysulfosuccinimide imparted an additional negative 
charge to targeting ligand and was designed to help solubilize the compound during the 
bioconjugation reaction. Unexpectedly the sulfo-NHS activated compounds failed to increase 
either the TAR or protein recovery measurements.   
 
Table 4.3. Recovered protein as a result of the varied immunoconjugation conditions. 
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 Ultimately the TAR of each batch was controlled through the amount of excess TL in the 
reaction. Most reactions with ten equivalents TL yielded a TAR of ~5. Doubling the amount of 
TL in the reaction proportionately increased resulting TAR. Table 4.4 illustrates these trends by 
listing the completed immunoconjugates. Both conjugates D13A and D26A were conjugation 
reactions with 10 equivalent TL on 10 mg antibody, and the TAR for each were measured at 4.58 
and 4.20 respectively. Reactions D13B and D26B were completed in parallel, only varying the 
excess TL (20 equivalents each).  Both D13B and D26B had a TAR of roughly 12. In this manner 
the control over TAR was followed for subsequent batches of immunoconjugates summarized in 
Table 4.4.  
 
4.2.3 Immunoconjugate Workup and Characterization: Size Exclusion 
 After the bioconjugation reaction of targeting ligand and antibody, the new conjugates 
were concentrated in Vivaspin 30 kDa MWCU centrifuge tubes. Unfortunately this method failed 
to adequately separate the excess, hydrolyzed targeting ligand from the substantially larger 
immunoconjugates.  Instead, some of the excess targeting ligand was observed to stick to the 
membrane of the filter as a blue precipitate.    
 A subsequent step of passing the concentrated immunoconjugate through a size exclusion 
column was necessary to remove the excess targeting ligand.  Due to the blue color of the targeting 
ligand, it was possible to observe the separation of immunoconjugates from the targeting ligand.  
The larger immunoconjugates eluted first, leaving a blue band of targeting ligand on the PD-10 
SEC column.  The collected fractions with immunoconjugate were concentrated and exchanged 
into 1x DPBS buffer using a Vivaspin column.   
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 Finally the purified immunoconjugates were run on an analytical scale SEC-HPLC column 
(TSKgel SuperSW3000) to confirm product homogeneity.  Examples of the separation observed 
between free antibody (A), free targeting ligand (B), and immunoconjugate (D) are shown in Figure 
4.5.  Box (C) also shows a coinjection of free targeting ligand and free antibody, demonstrating 
adequate separation using this method.  Final immunoconjugates were analyzed with this 
technique before going forward with further testing.  
 
 
Figure 4.5. Size exclusion experiment demonstrating the separation of conjugated and 
unconjugated immune effectors.   
 
 
4.2.4 Immunoconjugate Characterization: UV/Vis TAR Determination 
The most successful method of determining the TAR of the immunoconjugates used the 
UV/Vis absorbance of the final products.  Because the chromophores on the TL and the 
antibodies are different, maximally absorbing at 688 and 280 nm respectively, extinction 
coefficients (ɛ) for both components were determined experimentally (See Figure 4.6 for the linear 
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regressions used to calculate ɛ).  Through application of the Beer-Lambert equation, the absolute 
concentrations of each component in the immunoconjugate solution were determined. Finally, 
since the SEC analysis suggested that the components in the final immunoconjugate solution were 
attached, the relative concentrations of each were used to provide the average ratio of targeting 
ligand to antibody, or TAR.   
 
Figure 4.6. Experimental UV/Vis extinction coefficients for TAR calculations.   
 
The results of UV/Vis TAR determination for each completed immunoconjugate are listed 
in Table 4.4.  The majority of entries are conjugations with the αPD-1 antibody since the efficacy 
models of our collaborator (Dr. Amer Beg) were most pertinent to this immune effector.  
However, these modifications can be extended to other immune effectors as shown at the bottom 
of the table.  For instance, immunoconjugates of another checkpoint inhibitor class, αCD137, 
were also prepared (C119, D19). Additionally, another antibody designed to blockade a cognate 
receptor of Th expressed PD-1, αPDL-L, was also conjugated with TL.  Other immunoconjugates 
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prepared and listed in the table contain the scrambled TL (4.5). These conjugates were designed to 
be used as a non-targeting control in the efficacy model. Finally an α-trinitrophenol isotype control 
antibody was prepared for use as negative immune modulator conjugate.   
 
Table 4.4. Summary of immunoconjugates prepared. 
Notebook Entry Targeting Ligand mAb TAR 
Conc. 
(mg/mL) 
Comment 
C100 4.1 αPD-1 ND 2.07  
C106 4.2 αPD-1 5.18 9.11  
C114 4.3 αPD-1 6.20 7.28  
D9A 4.2 αPD-1 4.05 1.90  
D9B 4.2 αPD-1 9.03 6.59  
D13A 4.2 αPD-1 4.58 8.25  
D13B 4.2 αPD-1 12.9 6.36  
D26A 4.2 αPD-1 4.20 8.0  
D26B 4.2 αPD-1 11.0 8.0  
D40 4.5 αPD-1 30.5 2.6 Negative binding control 
D46 4.5 αPD-1 8.97 5.34 Negative binding control 
D49 4.2 αPD-1 10.9 4.00  
D51 4.4 αPD-1 9.51 5.08  
C119 4.3 αCD137 1.70 3.70  
D39 4.2 αCD137 4.20 8.21  
D38 4.2 αPD-L1 5.23 6.11  
D41 4.2 αTNP 5.43 3.26 Isotype control 
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4.2.5 Immunoconjugate Characterization: Mass Spec TAR Determination 
A secondary method useful for determining the TAR of immunoconjugates is mass 
spectrometry (MS). Initial efforts to characterize the immunoconjugates by MS for this project 
began with MALDI-TOF.  The results (not shown) were encouraging but peak shapes were too 
broad to be of real use in calculating TAR.  In the ADC field, HPLC-MS is becoming more 
common place but is still an area of active research. After studying previously reported electrospray 
ionization experiments in the literature,31-34 HPLC-QToF experiments were executed with the goal 
of determining the final immunoconjugate TAR and corroborating the UV/Vis data.   
One of the biggest challenges of measuring lysine-linked monoclonal antibody (mAb) 
immunoconjugates is the heterogeneity. Aside from the stochastic nature of the bioconjugation 
reactions, the starting mAbs have a large degree of glycosylation. These N-glycans are particularly 
pronounced in the Fc region of the antibodies and have been shown to be important for both the 
structural stability and function of the antibodies.35 Although fully intact antibodies were tested by 
HPLC-MS in this project, it was found that deglycosylating the immunoconjugates prior to MS 
analysis produced the cleanest spectra.  Two enzymes were used for deglycosylation in the project: 
IgGZero (Endo S) and PNGase F.  Both of these products are commercially available with the 
former marketed as a specific endoglycosidases for the Fc region of antibodies and the later a 
general purpose glycoprotein endoglycosidases.   
During the course of HPLC-QToF method development many different conditions, 
buffers, sample preps, and mass spectrometer conditions were tested.  Samples were worked up by 
either ZipTip, desalting Vivaspin columns, or miniature scale Sephadex G-25 packed syringes prior 
to being directly infused or injected on the HPLC front end of the MS instrument. Both a C8 
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protein (300 Å) RP-HPLC column and analytical scale SEC column were tested for 
chromatographing the analyte into the MS instrument. Various mobile phases consisting of water 
and acetonitrile were tested under buffered conditions ranging from trifluoroacetic acid (TFA), 
formic acid (FA), and ammonium formate.  Finally antibodies and immunoconjugates were tested 
as either intact molecules or as fragments that were reduced with TCEP and alkylated with 
iodoacetamide.  The optimized method that produced the highest quality spectrum consisted of 
the analytical scale SEC column using an isocratic mobile phase of ACN/H2O (50% + 0.1% TFA). 
The intact biomolecules were injected in their deglycosylation buffers and the MS instrument was 
cycled to waste when the buffer salts were eluted from the SEC method.   
 
Figure 4.7. MS analysis of deglycosylated αPD-1. 
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Once the analyte eluted into the mass spectrometer, the area under each total ion 
chromatogram (TIC) was integrated and a summed mass spectrum was produced.  A maximum 
entropy algorithm was then applied to produce a deconvoluted spectrum for each sample.  Figures 
4.7 and 4.8 show representative mass spectra for deglycosylated αPD-1 and an immunoconjugate 
consisting of αPD-1 and 4.5, respectively.   
 
 
Figure 4.8. MS analysis of deglycosylated immunoconjugate αPD-1 + 4.5 (D43). 
 
While the deconvoluted spectrum in Figure 4.8 shows successive peaks with repeating units 
corresponding to the mass of TL, it fails to corroborate the TAR calculated from the UV/Vis 
experiments.  Due to the nature of the bioconjugation reaction, a Gaussian distribution of 
deconvoluted peaks centered on the TAR was expected. Instead the deconvoluted peaks decay 
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from a peak corresponding to the unconjugated mAb mass.  These results may be linked to the 
sample preparation with the endoglycosidases, settings on the instrument itself, inherent 
differences in ionization potentials, or some other unknown factor.  Therefore the take away from 
these experiments was that the immunoconjugates consist of some covalently attached targeting 
ligands to mAbs. Since the analytical scale SEC experiments demonstrated that unbound targeting 
ligand was successfully removed during the workup, the UV/Vis analysis remains the most reliable 
method for TAR determination.   
 
4.2.6 Biological Testing of Immunoconjugates 
 This research wouldn’t be complete without a discussion on the biological testing of many 
of the newly created immunoconjugates. As with the previous research projects described in this 
dissertation, the novel compounds discussed in this chapter were tested in collaboration with 
research labs at the Moffitt Cancer Center. Biological testing of the immunoconjugates was done 
by two groups; each with a different specialty. Dr. Allison Cohen in the Morse group performed 
whole cell binding assays, engineered tumor cell lines to express mouse and human DOR, and 
performed in vivo fluorescence imaging studies. Dr. Hong Zheng in the Beg group developed the in 
vivo mouse efficacy studies. 
Figure 4.9 shows the binding assay results of two immunoconjugates, D13A and D13B, for 
whole cells expressing the DOR.  These two immunoconjugates had TARs of 4.6 and 12.9 
respectively. The assay not only demonstrates that the TL immunoconjugates retain the high 
binding affinities (18 and 4 nM respectively) of the TLs, but that they do so in a TAR dependent 
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fashion. The experiment further validates the postulate that higher TARs resulted in increased 
avidity of the immunoconjugate for the targeted receptor. 
 Box A in Figure 4.10 shows a representative in vivo image at 96 h post intravenous 
immunoconjugate injection to a mouse (n=4) with two flank xenografts. Immunoconjugate was 
observed by fluorescence in both denuded tumor implant areas and through the soles of the 
mouse’s feet.  The right tumor was engineered to express DOR(+) on the cell surface, and this 
tumor is shown to have substantially higher uptake of immunoconjugate than the DOR(-) tumor, 
left.  Box B of the figure shows the same tumors, excised, after 168 hours.  Box C of Figure 4.10 
quantifies the fluorescence uptake in the positive and negative tumors over the 168 h time course.  
In addition to higher levels of immunoconjugate in the positive tumor, Box C also indicates that 
free immunoconjugate was cleared from circulation after 96 h and a substantial portion remained 
at the positive tumors.   
 
 
Figure 4.9. Immunoconjugate competition binding assays for DOR expressing cells. Experiment 
performed by Allison Cohen (Morse Lab).   
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Figure 4.10. Differential uptake of immunoconjugate (D26A TAR 4.2) in DOR(-) and DOR(+) 
tumors. Experiment performed by Allison Cohen (Morse Lab).   
 
  
 Figure 4.11 reports the findings of an initial in vivo murine efficacy experiment performed 
by the Dr. Hong Zheng in the Beg lab.  The mice in this experiment had xenografted LKR tumors 
that did not express DOR. Box A in the figure shows tumor volume as a function of time for 
untreated animals (UT), and all tumors increased without inhibition. The three other boxes that 
comprise Figure 4.11 have similar trends with plateaued and decreased tumor growth after 
treatments. Boxes B and C show animals that had been treated with immunoconjugates of TARs 
4.58 and 12.9, respectively.  Box D in the bottom right shows animals that were treated with 
untargeted αPD-1.  The critical finding from this experiment was that the TL immunoconjugates 
retained functionality as immune modulators.  
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Figure 4.11. Comparison of immune modulator efficacy with and without TL in a mouse model. 
Experiment performed by Hong Zheng (Beg Lab).   
 
 
4.3 Conclusions 
 In summary, we have shown how simple modifications to a known peptide TL can make 
them amenable to bioconjugations with proteinaceous molecules.  Furthermore, the addition of 
fluorescent dye was shown to aide synthesis ease and characterization of products. The dye also 
yielded information about biodistribution and pharmacokinetics of the final immunoconjugates.  
This work outlines how TARs can be controlled through simple manipulations of buffers and 
targeting ligands. Finally, peptide ligands were shown to be able to target biomolecules 100 times 
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larger than themselves to extracellular targets, while retaining the functionality of the 
biomolecules.  
The experiments and immunoconjugates in this chapter demonstrate a novel manner in 
which peptide ligands can be used to deliver and concentrate immunomodulators to targeted cells.   
Not only does this project expand upon currently approved therapies for devastating diseases, but 
these conjugates open up a new platform technology. Going forward peptide, TL could be coupled 
not only with checkpoint inhibitors, but other immune modulators like interleukins or even 
engineered antibody fragments. Other advances in this field might include site-specific 
modifications to the biomolecules. Ultimately this pioneering work holds much promise for 
improving current immunotherapies.  
 
4.4 Experimental  
4.4.1 Materials and Instrumentation 
All purchased solvents and reagents were obtained at ACS grade or higher purity level and 
used without further purification unless specified otherwise. Antibodies were purchased from 
BioXCell (www.bxcell.com).  Fluorescent dye was purchased from Lumiprobe. Peptide coupling 
reagents and amino acids were obtained from either Chem-Impex or AnaSpec. Distilled NMP 
(99.96%) was purchased from Chem-Impex.  Tentagel Resin was obtained from Rapp Polymere.  
HPLC grade Acetonitrile was purchased from or Fisher was used for HPLC and de-ionized water 
was processed by Millipore Milli-Q water purifier for HPLC. 
A Varian solvent delivery module with Dionex UVD340U diode array detector was used 
for preparative HPLC chromatography.  Analytical scale HPLC was performed using either a 
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Dionex P680 system or an Agilent 1200 system, both with quaternary pumps, autosamplers, and 
diode array detectors.  Mass spectral analysis was performed with either Agilent 6540 QTOF  with 
dual Jet-Stream ESI source coupled to Agilent 1260 Infinity HPLC, Agilent LC/MSD VL single 
quadrupole with Agilent 1100 series HPLC, or Applied Biosystem 4700 MALDI-TOF-TOF 
proteomics analyzer with 355nm Nd:YAG laser. Peptides were lyophilized on a Labconco Freeze 
Dry/Shell Freeze System.  Absorbance and Fluorescence measurements were taken on a Tecan 
Infinite M-1000 PRO multimode microplate reader.  
 
4.4.2 Experimental Procedures 
4.4.2.1 Targeting Ligand (TL) Synthesis. Peptide TLs were synthesized with conventional 
Nα-Fmoc solid phase peptide synthesis according to Scheme 4.1.  Standard TentaGel Rink amide 
resin (0.5-1 g) with substitution of 0.24 mmol/g was swollen in DCM (10-15 mL) followed by N- 
methyl-2-pyrrolidinone (10-15 mL). All mixing resulted from gentle agitation of bubbled Ar (g) in a 
glass-fritted peptide reaction vessel.  Fmoc-protecting groups were removed by reaction with 20% 
piperidine, 2% DBU in NMP for 15min (x2).  Following Fmoc deprotection, a typical washing 
step consisting of 15 mL each: NMP (3x), DCM (3x), NMP (3x) was performed.  Next Fmoc-
Lys(Alloc)-OH (5x eq) was coupled for 2 h with activation from HCTU (5 eq) and NMM (15 eq). 
Qualitative Kaiser Assay was performed on several resin beads to ensure complete reaction. This 
cycle of washing, Fmoc-deprotection, washing, and coupling was repeated for the Fmoc- 1,2,3,4-
tetrahydroisoquinoline-3-OH (TIC). The next amino acid (4 eq), Fmoc-(2,6-diMethyl)Tyrosine-OH 
(Dmt), was coupled for 2 h after preparing the symmetric anhydride with  DCC (2 eq). The 
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scrambled TL was synthesized in an analogous fashion by reversing the order of amino acids: 
Fmoc-Dmt-OH, Fmoc-Tic-OH, Fmoc-Lys(Alloc)-OH.   
 The N-terminus of each on-resin intermediate was dimethylated through reductive 
amination in Ar (g) agitated NMP.  Three hundred microliters of 37% formaldehyde per gram of 
resin was added to the reaction along with NaCNBH3 (5eq).  Catalytic AcOH was added dropwise 
and the reaction was left for 4 hours.  
 After methylation, the alloc protection group was removed by treatment with Pd(0)(PPh3)4 
(5 mol%), 5 drops of piperidine, and 10 mL DCM for 1 hour. The resin was washed in the typical 
manner, with the addition of 2x 15 mL, 5 mol% sodium diethyldithiocarbamate in NMP and 10% 
DIEA. Qualitative Kaiser assay and a small-test cleavage for MALDI-TOF analysis were used to test 
peptide purity.  At this stage, the peptide was either branched once more with the HCTU activated 
coupling of Fmoc-Lys(Alloc)-OH or capped by discrete PEG monomer. After the former, the alloc 
group was removed as previously described.  The symmetric anhydride of dPEG monomer was 
synthesized as described by DCC condensation and coupled to the resin. Finally, peptides were 
cleaved from the resin with a cocktail of TFA, H2O, and triisopropylsilane (95:2.5:2.5, v/v).   
 Peptides were characterized and purified by RP-HPLC, followed by MALDI-TOF analysis 
and lyophilization as described in chapter 2.  For compounds 4.2 – 4.5, pure peptide powder was 
reconstituted in acetonitrile (1 mL) with Cyanine5.5 NHS ester (1.2 eq) and TEA (10 eq).  The 
reactions were monitored for completion by linear gradient HPLC. Once starting material was 
consumed, the acetonitrile was diluted with H2O, frozen, and lyophilized.  The resulting blue 
powder was purified by semi-preparative HPLC with a linear gradient of H2O and ACN with 0.1% 
TFA.  Fractions with purity greater than 95% were collected by hand, frozen and lyophilized.  
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Finally, dried blue powder was activated with either N-hydroxysuccinimide or N-
hydroxysulfosuccinimide. This reaction was carried out in minimal ACN with EDAC (5 eq) and 
NHS/sulfo-NHS (5 eq).  Once again the reaction was monitored by retention time shift on a linear 
gradient of HPLC and once complete, purified by HPLC and lyophilized. The final, activated, 
peptide TLs (Table 4.1) were dissolved in dry DMSO to make 5 mM stock solutions. They were 
protected from UV light and kept at -20 °C until use.   
 
4.4.3.2 General Antibody Conjugation Protocol.  Immunoconjugates were prepared in 
buffered aqueous solutions with organic solvent modifiers.  The generalized reaction media that 
resulted in the most efficient reactions consisted of 50 mM phosphate buffered to pH 8 with 50% 
ethylene glycol.  Purchased antibodies were first exchanged (2x) into phosphate buffer by 
centrifugation in Vivaspin 6 or 20, 30kDa MWCO tubes (GE Healthcare).  Then the antibodies 
were reconstituted to 4 mg/mL in the 50% ethylene glycol, phosphate buffer.  Ten to twenty 
equivalents of activated TL stock solution (5 mM) were added dropwise to the mechanically stirred 
solutions.  The reactions were protected from light and stirred overnight at room temperature. 
 
4.4.3.3 General Immunoconjugate Purification Protocol. The crude reaction solution 
was first concentrated by centrifugation in Vivaspin 20, 30kDa MWCO tubes.  Samples were 
loaded into the upper section of the tube and diluted with 1x DPBS; then spun at 4000 for 40 min 
at 25 min. This resulted in a concentrated solution of about 2 mL to load onto the size exclusion 
columns.   
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 PD-10 (GE Healthcare) desalting columns containing 8.3 mL of prepacked Sephadex™ G-
25 size exclusion gel were used to separate conjugated antibodies from excess targeting ligand.  
Prior to loading, the columns were equilibrated with 25 mL mobile phase, 10% ethanol in 1x 
DPBS.  The crude samples were loaded onto PD-10 column as a concentrated band and allowed to 
penetrate the column bed before the addition of more mobile phase. Then the column was 
allowed to run by gravity and ~1 mL fractions were collected manually.  Two sets fractions with 
clear blue tint were collected for each respective immunoconjugate.    
Due to its larger molecular weight, the first band of blue fractions was combined and 
further characterized by SEC-HPLC.  The Agilent analytical HPLC system was coupled with 
TSKgel SuperSW3000 size exclusion column (30cm x 4.6mm, 4µm) to assay components in eluted 
fractions.  Analysis was done by injecting 50 µg of compound on an isocratic elution of 50% 
ACN/H2O and 0.1% TFA at 0.3 mL/min flow rate.  Eluent was monitored by absorbance at 280 
nm and fluorescence at 352/708 nm (emission and excitation respectively). Figure 4.5 shows 
typical separation of free targeting ligand, free antibody, and immunoconjugates. The combined 
fractions were then exchanged into 1x DPBS through 3 centrifugation steps with Vivaspin 20, 
30kDa MWCO tubes.  Final immunoconjugates were stored at 4 °C and protected from UV light.   
  
4.4.3.4 Immunoconjugate TAR Determination: UV/Vis. Absorbance and fluorescence 
emission spectra were measured for TL, antibodies, and immunoconjugates. Samples were spotted 
(4 µL) in triplicate on a Tecan Nanoquant plate with a pathlength of 0.05 cm. Blanks were 
subtracted from sample measurements. Absorbance measurements were collected from 230 to 
1000 nm with a 2 nm step size.  Emission spectra were collected from 500 to 850 nm with 2 nm 
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step size and 361 nm excitation wavelength.  Extinction coefficients were calculated at 280 nm and 
688 nm by plotting the linear regression of serially diluted samples from 0.1 – 2 mM.  
Manipulation of the Beer-Lambert equation, A = ε x c x l (A, absorbance at specified wavelength; ε, 
extinction coefficient; c, concentration; l, path length) was used to give the following systems of 
equations where the TAR could be solved for by determining the ratio of concentrations of 
peptide to mAb. 
 
A280nm= (ε280nm,Pep x Cpep  + ε280nm, mAb x CmAb)  
A680nm= (ε680nm,Pep x Cpep  + ε680nm, mAb x CmAb)  
TAR = Cpep / CmAb 
 
4.4.3.5 Immunoconjugate TAR Determination: Mass Spectrometry. Antibodies and 
immunoconjugates were prepared for mass spectral analysis by deglycosylation using PNGase F 
enzyme.  Proteins were exchanged into 40 mM HEPES buffer, pH 7.5, at concentration of 2 
mg/mL.  Enzyme was added (500 units/100 µg) and each solution was incubated at 37 °C for 24 
h.  Finally the solution was diluted 1:1 with mobile phase from the SEC separation (50% ACN + 
0.1% TFA).   
 The QToF instrument was coupled with the SEC column on the front end HPLC as 
previously described. The dual Jet Stream ESI mass spectrometer source was set according to the 
parameters in Table 4.5.  Antibody and immunoconjugates were injected 20 µg per experiment 
and eluted under isocratic condition of 50% ACN + 0.1% TFA at 0.3 mL/min. Data was collected 
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in 2 GHz extended mass range mode (1000-8000 m/z) using MassHunter Workstation Version 
B.05.01. 
Analysis of antibodies and immunoconjugates was performed with Agilent MassHunter 
Qualitative Analysis version B.05.00 with Bioconfirm.  The analysis method was set to 
BioConfirnIntactProteinHighMass-default.  Regions of protein elution in the TIC (total ion 
chromatogram) were manually integrated, extracted, and background subtracted. Each resulting 
spectrum was subsequently deconvoluted using the Maximum Entropy feature.  The mass range 
was set to 130-160 kDa with a mass step of 1 Da and a S/N threshold of 1.0.  Proton adducts  with 
an average mass of  25% peak height were specified.   
 
Table 4.5. Source and TOF parameters used for antibody and immunoconjugate MS analysis. 
Parameter Setting 
Gas Temperature 300 °C 
Drying Gas 13 L/min 
Nebulizer 45 psig 
Sheath Gas Temp 400 °C 
Sheath Gas Flow 12 L/min 
Capillary Voltage 5500 V 
Fragmentor Voltage 300 V 
Skimmer Voltage 250 V 
Octopole RF Peak 750 V 
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4.5 Targeting Ligand Structures 
 
 
 
 
N,N-DiMethyl-Dmt-Tic-Lys(dPEG5-NHS)-CONH2 Targeting Ligand, 4.1 
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N,N-DiMethyl-Dmt-Tic-Lys(Lys(Cy5.5)-dPEG5-NHS)-CONH2 Targeting Ligand, 4.2 
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N,N-DiMethyl-Dmt-Tic-Lys(Lys(Cy5.5)-dPEG5-SulfoNHS)-CONH2 Targeting Ligand, 4.3 
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N,N-DiMethyl-Dmt-Tic-Lys(Lys(Cy5.5)-dPEG13-NHS)-CONH2 Targeting Ligand, 4.4 
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N,N-DiMethyl-Lys(Lys(Cy5.5)-dPEG5)-Tic-Dmt-CONH2, Scrambled Targeting Ligand, 4.5 
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APPENDIX A: 
SELECTED MASS SPECTRA AND HPLC CHROMATOGRAMS OF PEPTIDE TARGETING 
LIGANDS 
 
 
 
Figure A2.1 MC1RL; Mass Spectrum 
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Figure A2.2 MC1RL; HPLC Trace 
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Figure A2.3 MC1RL-Ahx-FBA; Mass Spectrum 
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Figure A2.4 MC1RL-Ahx-FBA; HPLC Trace 
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Figure A2.5 MC1RL-Ahx-DTPA; Mass Spectrum 
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Figure A2.6 MC1RL-Ahx-DTPA:Eu; Mass Spectrum 
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Figure A2.7 MC1RL-Ahx-DTPA:Eu; HPLC Trace 
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Figure A2.8 MC1RL-Ahx-DOTA; Mass Spectrum 
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Figure A2.9 MC1RL-Ahx-DOTA; HPLC Trace 
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Figure A2.10 Scrambled-MC1RL-Ahx-DOTA; Mass Spectrum (prepared by Dr. Hunjoo Kil) 
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Figure A2.11 Scrambled-MC1RL-Ahx-DOTA; HPLC Trace (prepared by Dr. Hunjoo Kil) 
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Figure A2.12 MC1RL(D5)-Ahx-DOTA; Mass Spectrum  
137 
 
 
Figure A2.13 MC1RL(D5)-Ahx-DOTA; HPLC Trace 
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Figure A2.14 MC1RL-Ahx-DOTA:La; Mass Spectrum 
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Figure A2.15 MC1RL-Ahx-DOTA:La; HPLC Trace 
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Figure A2.16 MC1RL-Ahx-DOTA:Ga; Mass Spectrum 
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Figure A2.17 MC1RL-Ahx-DOTA:Ga; HPLC Trace 
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Figure A2.18 MC1RL-Ahx-DOTA:Eu; Mass Spectrum 
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Figure A2.19 MC1RL-Ahx-DOTA:Eu; HPLC Trace 
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Figure A2.20 MC1RL-Ahx-DOTA:In; Mass Spectrum 
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Figure A2.21 MC1RL-Ahx-DOTA:In; HPLC Trace 
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Figure A2.22 MC1RL-diDGlu-DOTA; Mass Spectrum (prepared by Dr. Hunjoo Kil) 
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Figure A2.23 MC1RL-diDGlu-DOTA; HPLC Trace (prepared by Dr. Hunjoo Kil) 
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Figure A2.24 MC1RL-diDGlu-DOTA:In; Mass Spectrum (Precursor prepared by Dr. Hunjoo Kil) 
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Figure A2.25 MC1RL-diDGlu-DOTA:In; HPLC Trace (Precursor prepared by Dr. Hunjoo Kil) 
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Figure A2.26 MC1RL-diDLys-DOTA; Mass Spectrum (Precursor prepared by Dr. Hunjoo Kil) 
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Figure A2.27 MC1RL-diDLys-DOTA; HPLC Trace (Precursor prepared by Dr. Hunjoo Kil) 
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Figure A2.28 MC1RL-DOTA; Mass Spectrum  
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Figure A2.29 MC1RL-DOTA; HPLC Trace 
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Figure A2.30 MC1RL-DOTA:La; HPLC Trace 
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Figure A2.31 MC1RL-DOTA:La; HPLC Trace 
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Figure A2.32 MC1RL-DOTA:Ga; Mass Spectrum 
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Figure A2.33 MC1RL-DOTA:Ga; HPLC Trace 
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Figure A2.34 MC1RL-DOTA:Eu; Mass Spectrum  
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Figure A2.35 MC1RL-DOTA:Eu; HPLC Trace  
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Figure A2.36 MC1RL-DOTA:In; Mass Spectrum  
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Figure A2.37 MC1RL-DOTA:In; HPLC Trace  
162 
 
 
Figure A2.38 cMC1RL-B43-cyclic; Mass Spectrum 
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Figure A2.39 cMC1RL-B43-cyclic; HPLC Trace 
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Figure A2.40 cMC1RL-B43-linear; Mass Spectrum 
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Figure A2.41 cMC1RL-B43-linear; HPLC Trace 
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Figure A2.42 cMC1RL-B52-cyclic; Mass Spectrum 
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Figure A2.43 cMC1RL-B52-cyclic; HPLC Trace 
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Figure A2.44 cMC1RL-B52-linear; Mass Spectrum  
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Figure A2.45 cMC1RL-B52-linear; HPLC Trace 
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Figure A2.46 cMC1RL-B53-cyclic; Mass Spectrum  
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Figure A2.47 cMC1RL-B53-cyclic; HPLC Trace 
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Figure A2.48 cMC1RL-B53-linear; Mass Spectrum 
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Figure A2.49 cMC1RL-B53-linear; HPLC Trace 
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Figure A2.50 cMC1RL-B53-cyclic; Mass Spectrum 
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Figure A2.51 cMC1RL-B53-cyclic; HPLC Trace 
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Figure A2.52 cMC1RL-B54-linear; Mass Spectrum 
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Figure A2.53 cMC1RL-B54-linear; HPLC Trace 
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Figure A3.1.TLR2L-780; Mass Spectrum 
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Figure A4.1 Peptide 4.2; Mass Spectrum 
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Figure A4.2 Peptide 4.2; HPLC Trace 
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Figure A4.3 Peptide 4.3; Mass Spectrum 
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Figure A4.4 Peptide 4.3; HPLC Trace 
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Figure A4.5 Peptide 4.4; Mass Spectrum 
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Figure A4.6 Peptide 4.4; HPLC Trace 
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Figure A4.7 Peptide 4.5; Mass Spectrum 
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Figure A4.8 Peptide 4.5; HPLC Trace 
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SELECTED 1H AND 13C NMR SPECTRA 
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 Figure B3.5 1H NMR (400 MHz, CDCl3) spectrum of 3.3 
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  Figure B3.6  13C {1H} NMR (101 MHz, CDCl3) spectrum of 3.3 
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Figure B3.7 1H NMR (500 MHz, CDCl3) spectrum of 3.4 
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  Figure B3.8 13C {1H} NMR (151 MHz, CDCl3) spectrum of 3.4 
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Figure B3.9 1H NMR (500 MHz, CDCl3) spectrum of 3.5 
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Figure B3.10  13C {1H} NMR (151 MHz, CDCl3) spectrum of 3.5 
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Figure B3.11. 1H NMR (500 MHz, CDCl3) spectrum of 3.6 
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Figure B3.12 13C {1H} NMR (126 MHz, CDCl3) spectrum of 3.6 
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Figure B3.13 1H NMR (600 MHz, DMSO) spectrum of 3.7 
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 Figure B3.14 13C {1H} NMR (151 MHz, CDCl3) spectrum of 3.7 
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APPENDIX C: 
 
 
SELECTED ANTIBODY AND IMMUNOCONJUGATE CHARACTERIZATION 
 
 
 
Figure C4.1 α-PD-L1 antibody; Mass Spectra  
202 
 
 
Figure C4.2 α-CD137L antibody; Mass Spectra 
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Figure C4.3 α-trinitrophenol antibody; Mass Spectra 
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Figure C4.4 Immunoconjugate α-trinitrophenol + DmtTic (4.2), D41; Mass Spectra 
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Figure C4.5 Immunoconjugate α-PDL-1 + DmtTic (4.2), D38; Mass Spectra 
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Figure C4.6 Immunoconjugate α-PD-1 + DmtTic (4.2), D13A; SEC Chromatograph 
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Figure C4.7 Immunoconjugate α-PD-1 + DmtTic (4.2), D13B; SEC Chromatograph 
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Figure C4.8 Immunoconjugate α-PD-1 + DmtTic (4.2), D26A; SEC Chromatograph 
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Figure C4.9 Immunoconjugate α-PD-1 + DmtTic (4.2), D26B; SEC Chromatograph 
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Figure C4.10 Immunoconjugate α-PDL-1 + DmtTic (4.2), D38; SEC Chromatograph 
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Figure C4.11 Immunoconjugate α-CD137L + DmtTic (4.2), D39; SEC Chromatograph 
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Figure C4.12 Immunoconjugate α-PD-1 + scrambled-DmtTic (4.5), D40; SEC Chromatograph 
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Figure C4.13 Immunoconjugate α-trinitrophenol + DmtTic (4.2), D41; SEC Chromatograph 
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Figure C4.14 Immunoconjugate α-PD-1 + scrambled-DmtTic (4.5), D46; SEC Chromatograph 
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Figure C4.15 Immunoconjugate α-PD-1 + DmtTic (4.2), D49; SEC Chromatograph 
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Figure C4.16 Immunoconjugate α-PD-1 + DmtTic (4.4), D51; SEC Chromatograph
217 
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Figure D1 MC1RL IACUC Approval 
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Figure D2 TLR2L IACUC Approval 
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Figure D3 DORL IACUC Approval 
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Figure D4 DORL IACUC Approval Renewal 
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